{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:27:45Z","timestamp":1793924865825,"version":"4.8.0"},"reference-count":426,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.vaccine.2026.129113","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:30:09Z","timestamp":1791891009000},"page":"129113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["rVSV-\u0394G-EBOV-GP-Nipah-G (also designated PHV02) replication-competent, recombinant vesicular stomatitis virus vaccine for prevention of Nipah virus disease: Standardized template with key considerations for a risk\/benefit assessment"],"prefix":"10.1016","volume":"94","author":[{"given":"Thomas P.","family":"Monath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Erbelding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Gray","family":"Heppner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"DeVries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Crowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Scappaticci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaddeus G.","family":"Pullano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily R.","family":"Wellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen C.","family":"Farnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Karuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.129113_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2019.100009","volume":"1","author":"Monath","year":"2019","journal-title":"Vaccine X"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/imm.12829","article-title":"Novel viral vectors in infectious diseases","volume":"153","author":"Humphreys","year":"2018","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129113_bb0015","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/sj.gt.3301390","article-title":"Efficient gene transfer of VSV-G pseudotyped retroviral vector to human brain tumor","volume":"8","author":"Lee","year":"2001","journal-title":"Gene Ther"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0020","doi-asserted-by":"crossref","first-page":"2469416","DOI":"10.1080\/21645515.2025.2469416","article-title":"Harnessing live vectors for cancer vaccines: advancing therapeutic immunotherapy","volume":"21","author":"Jani","year":"2025","journal-title":"Hum Vaccin Immunother"},{"issue":"42","key":"10.1016\/j.vaccine.2026.129113_bb0025","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1016\/j.vaccine.2019.08.018","article-title":"Clinical trials with GMO-containing vaccines in europe: status and regulatory framework","volume":"37","author":"Kauffmann","year":"2019","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/02648725.2018.1471643","article-title":"Vaccinia-based vaccines to biothreat and emerging viruses","volume":"34","author":"Nagata","year":"2018","journal-title":"Biotechnol Genet Eng Rev"},{"issue":"9\u201310","key":"10.1016\/j.vaccine.2026.129113_bb0035","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.micinf.2018.01.005","article-title":"Measles-derived vaccines to prevent emerging viral diseases","volume":"20","author":"Frantz","year":"2018","journal-title":"Microbes Infect"},{"issue":"34","key":"10.1016\/j.vaccine.2026.129113_bb0040","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1016\/j.vaccine.2012.06.001","article-title":"Recombinant canine distemper virus serves as bivalent live vaccine against rabies and canine distemper","volume":"30","author":"Wang","year":"2012","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129113_bb0045","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1128\/JVI.03656-14","article-title":"Parainfluenza virus 5 expressing the g protein of rabies virus protects mice after rabies virus infection","volume":"89","author":"Huang","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.129113_bb0050","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.virusres.2014.02.016","article-title":"Newcastle disease virus: current status and our understanding","volume":"184","author":"Ganar","year":"2014","journal-title":"Virus Res"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129113_bb0055","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.vaccine.2009.11.037","article-title":"Stable expression of a foreign protein by a replication-competent rubella viral vector","volume":"28","author":"Spadaccini","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129113_bb2100","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2019.197662","article-title":"Characterization of a replication-competent vector encoding DsRed based on a human adenovirus type 4 a-like strain","volume":"270","author":"Tian","year":"2019","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2026.129113_bb0060","doi-asserted-by":"crossref","unstructured":"Lundstrom K. Alphavirus-based vaccines. Viruses. 2014;6(6):2392-2415. Published 2014. doi:https:\/\/doi.org\/10.3390\/v6062392.","DOI":"10.3390\/v6062392"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb2105","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41541-021-00282-y","article-title":"A single-dose live attenuated chimeric vaccine candidate against zika virus","volume":"6","author":"Chin","year":"2021","journal-title":"NPJ Vaccines."},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0065","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.vaccine.2014.10.004","article-title":"Brighton collaboration viral vector vaccines safety working group (V3SWG). Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk\/benefit assessment","volume":"33","author":"Monath","year":"2015","journal-title":"Vaccine"},{"issue":"44","key":"10.1016\/j.vaccine.2026.129113_bb0070","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.1016\/j.vaccine.2019.09.027","article-title":"Stabilization and formulation of a recombinant human cytomegalovirus vector for use as a candidate HIV-1 vaccine","volume":"37","author":"Kumru","year":"2019","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0075","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12985-020-01450-7","article-title":"The recombinant pseudorabies virus expressing african swine fever virus CD2v protein is safe and effective in mice","volume":"17","author":"Feng","year":"2020","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2026.129113_bb0080","doi-asserted-by":"crossref","first-page":"15327","DOI":"10.1038\/ncomms15327","article-title":"Replicating viral vector platform exploits alarmin signals for potent CD8+ t cell-mediated tumour immunotherapy","volume":"8","author":"Kallert","year":"2017","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129113_bb0085","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1128\/JVI.76.4.1649-1662.2002","article-title":"Novel design architecture for genetic stability of recombinant poliovirus: the manipulation of G\/C contents and their distribution patterns increases the genetic stability of inserts in a poliovirus-based RPS-Vax vector system","volume":"76","author":"Lee","year":"2002","journal-title":"J Virol"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2026.129113_bb0090","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.virusres.2010.06.017","article-title":"Vectored vaccines to protect against PRRSV","volume":"154","author":"Cruz","year":"2010","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2026.129113_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.vetmic.2019.108549","article-title":"Immune responses in mice and pigs after oral vaccination with rabies virus vectored nipah disease vaccines","volume":"241","author":"Shuai","year":"2020","journal-title":"Vet Microbiol"},{"issue":"40","key":"10.1016\/j.vaccine.2026.129113_bb0100","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1016\/j.vaccine.2023.08.038","article-title":"Newcastle disease virus (NDV) recombinant expressing marek\u2019s disease virus (MDV) glycoprotein b significantly protects chickens against MDV and NDV challenges","volume":"41","author":"He","year":"2023","journal-title":"Vaccine"},{"issue":"51","key":"10.1016\/j.vaccine.2026.129113_bb0105","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1016\/j.vaccine.2016.06.071","article-title":"Brighton collaboration viral vector vaccines safety working group. Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: standardized template with key considerations for a risk\/benefit assessment","volume":"34","author":"Clarke","year":"2016","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2026.129113_bb0110","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1080\/14760584.2016.1175943","article-title":"DNA-launched live-attenuated vaccines for biodefense applications","volume":"15","author":"Pushko","year":"2016","journal-title":"Expert Rev Vaccines"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129113_bb0115","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1080\/21645515.2019.1649532","article-title":"Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens","volume":"15","author":"Fathi","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129113_bb0120","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1128\/JVI.73.5.3723-3732.1999","article-title":"Attenuated vesicular stomatitis viruses as vaccine vectors","volume":"73","author":"Roberts","year":"1999","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0125","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1586\/erv.10.152","article-title":"Progress in filovirus vaccine development: evaluating the potential for clinical use","volume":"10","author":"Falzarano","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0130","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1146\/annurev-virology-021920-113833","article-title":"Vaccines to emerging viruses: Nipah and hendra","volume":"7","author":"Amaya","year":"2020","journal-title":"Annu Rev Virol."},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0135","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/01652176.2019.1580827","article-title":"Nipah virus: epidemiology, pathology, immunobiology and advances in diagnosis, vaccine designing and control strategies - a comprehensive review","volume":"39","author":"Singh","year":"2019","journal-title":"Vet Q"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129113_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2025.117141","article-title":"Nipah virus as a pandemic threat: current knowledge, diagnostic gaps, and future research priorities","volume":"114","author":"Asokan","year":"2026","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129113_bb0145","series-title":"Advances in patient safety: From research to implementation (volume 2: Concepts and methodology)","article-title":"The Brighton collaboration: Creating a global standard for case definitions (and guidelines) for adverse events following immunization","author":"Kohl","year":"2005"},{"issue":"22","key":"10.1016\/j.vaccine.2026.129113_bb0150","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1016\/j.vaccine.2020.10.072","article-title":"The Brighton collaboration standardized templates for collection of key information for benefit-risk assessment of vaccines by technology (BRAVATO; formerly V3SWG)","volume":"39","author":"Chen","year":"2021","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129113_bb0155","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.vaccine.2023.09.039","article-title":"The Brighton collaboration standardized module for vaccine benefit-risk assessment","volume":"42","author":"Levitan","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129113_bb0160","series-title":"WHO prequalifies Ebola vaccine, paving the way for its use in high-risk countries","author":"Jasarevic","year":"2019"},{"issue":"49","key":"10.1016\/j.vaccine.2026.129113_bb0165","doi-asserted-by":"crossref","first-page":"7708","DOI":"10.1016\/j.vaccine.2020.08.009","article-title":"Brighton collaboration benefit-risk assessment of vaccines by technology (BRAVATO) working group. The Brighton collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines","volume":"38","author":"Condit","year":"2020","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.vaccine.2026.129113_bb0170","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1016\/j.vaccine.2020.08.050","article-title":"Brighton collaboration viral vector vaccines safety working group V3SWG. The Brighton collaboration standardized template for collection of key information for risk\/benefit assessment of a modified vaccinia Ankara (MVA) vaccine platform","volume":"39","author":"Volkmann","year":"2021","journal-title":"Vaccine"},{"issue":"34","key":"10.1016\/j.vaccine.2026.129113_bb2110","doi-asserted-by":"crossref","first-page":"5556","DOI":"10.1016\/j.vaccine.2020.06.017","article-title":"Brighton collaboration viral vector vaccines safety working group (V3SWG). The Brighton collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines","volume":"38","author":"Kim","year":"2020","journal-title":"Vaccine"},{"issue":"35","key":"10.1016\/j.vaccine.2026.129113_bb0175","doi-asserted-by":"crossref","first-page":"5248","DOI":"10.1016\/j.vaccine.2022.06.008","article-title":"(Benefit-risk assessment of VAccines by TechnolOgy working group BRAVATO, ex-V3SWG). Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: standardized template with key considerations for a risk\/benefit assessment","volume":"40","author":"Folegatti","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129113_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127137","volume":"58","author":"Spurgers","year":"2025","journal-title":"Vaccine"},{"issue":"38","key":"10.1016\/j.vaccine.2026.129113_bb0185","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1016\/j.vaccine.2021.07.030","volume":"39","author":"Eldridge","year":"2021","journal-title":"Vaccine"},{"issue":"35","key":"10.1016\/j.vaccine.2026.129113_bb0190","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1016\/j.vaccine.2022.06.005","article-title":"Benefit-risk assessment of VAccines by TechnolOgy working group BRAVATO ex-V3SWG. A Brighton collaboration standardized template with key considerations for a benefit\/risk assessment for the moderna COVID-19 vaccine (mRNA-1273)","volume":"40","author":"Leav","year":"2022","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.vaccine.2026.129113_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126165","article-title":"Benefit-risk assessment of VAccines by TechnolOgy working group (BRAVATO; ex-V3SWG). A Brighton collaboration standardized template with key considerations for a benefit-risk assessment for the comirnaty COVID-19 mRNA vaccine","volume":"42","author":"Pather","year":"2024","journal-title":"Vaccine"},{"issue":"35","key":"10.1016\/j.vaccine.2026.129113_bb0200","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1016\/j.vaccine.2022.06.006","article-title":"Benefit-risk assessment of VAccines by TechnolOgy working group (BRAVATO, ex-V3SWG). A Brighton collaboration standardized template with key considerations for a benefit\/risk assessment for an inactivated viral vaccine against chikungunya virus","volume":"40","author":"Hernandez","year":"2022","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0205","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s42269-023-01064-3","article-title":"Langya virus outbreak: current challenges and lesson learned from previous henipavirus outbreaks in China, Australia, and southeast asia","volume":"47","author":"Adesola","year":"2023","journal-title":"Bull Natl Res Cent"},{"key":"10.1016\/j.vaccine.2026.129113_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2022.106882","article-title":"Langya virus, a newly identified henipavirus in China - zoonotic pathogen causing febrile illness in humans, and its health concerns: current knowledge and counteracting strategies - correspondence","volume":"105","author":"Chakraborty","year":"2022","journal-title":"Int J Surg"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129113_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002739","article-title":"Evidence of henipavirus infection in west african fruit bats","volume":"3","author":"Hayman","year":"2008","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2026.129113_bb0220","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1038\/ncomms6342","article-title":"Evidence for henipavirus spillover into human populations in africa","volume":"5","author":"Pernet","year":"2014","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129113_bb0225","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3201\/eid1307.061128","article-title":"Person-to-person transmission of nipah virus in a bangladeshi community","volume":"13","author":"Gurley","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129113_bb0230","first-page":"335","article-title":"Update: outbreak of nipah virus-Malaysia and Singapore, 1999","volume":"48","author":"Centers for Disease Control and Prevention","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2026.129113_bb0235","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(99)04379-2","article-title":"Outbreak of nipah-virus infection among abattoir workers in Singapore","volume":"354","author":"Paton","year":"1999","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129113_bb0240","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1086\/315457","article-title":"Case-control study of risk factors for human infection with a new zoonotic paramyxovirus, nipah virus, during a 1998-1999 outbreak of severe encephalitis in Malaysia","volume":"181","author":"Parashar","year":"2000","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb0245","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0749-0739(17)30098-6","article-title":"Hendra and nipah virus infections","volume":"16","author":"Hooper","year":"2000","journal-title":"Vet Clin North Am Equine Pract"},{"key":"10.1016\/j.vaccine.2026.129113_bb0250","article-title":"Single-dose mucosal replicon-particle vaccine protects against lethal nipah virus infection up to 3 days after vaccination","volume":"9(31):eadh4057","author":"Welch","year":"2023","journal-title":"Sci Adv"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb0255","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3390\/vaccines9030190","article-title":"Development of pandemic vaccines: ERVEBO case study","volume":"9","author":"Wolf","year":"2021","journal-title":"Vaccines (Basel)."},{"key":"10.1016\/j.vaccine.2026.129113_bb0260","doi-asserted-by":"crossref","unstructured":"Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Gsell PS, Hossmann S, Watle SV, Kond\u00e9 MK, K\u00e9\u00efta S, Kone S, Kuisma E, Levine MM, Mandal S, Mauget T, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, R\u00f8ttingen JA, Kieny MP. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!). Lancet. 2017;389(10068):505-518. Erratum in: Lancet. 2017;389(10068):504. Erratum in: Lancet. 2017;389(10068):504.","DOI":"10.1016\/S0140-6736(16)32621-6"},{"key":"10.1016\/j.vaccine.2026.129113_bb0265","article-title":"Clinical development of a recombinant ebola vaccine in the midst of an unprecedented epidemic","volume":"35(35 Pt A):4465-4469","author":"Coller","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129113_bb0270","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2217\/fmb-2019-0237","article-title":"Safety, immunogenicity and risk-benefit analysis of rVSV-\u0394G-ZEBOV-GP (v920) ebola vaccine in phase I-III clinical trials across regions","volume":"15","author":"Bache","year":"2020","journal-title":"Future Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7001a1","article-title":"Use of ebola vaccine: recommendations of the advisory committee on immunization practices, United States, 2020","volume":"70","author":"Choi","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2026.129113_bb0280","unstructured":"Merck Sharp & Dohme Corp. ERVEBO (Ebola Zaire vaccine, live) prescribing information. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2019."},{"issue":"27","key":"10.1016\/j.vaccine.2026.129113_bb0285","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1016\/j.vaccine.2018.05.095","article-title":"A recombinant virus vaccine that protects against both chikungunya and zika virus infections","volume":"36","author":"Chattopadhyay","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129113_bb0290","article-title":"Architecture and antigenicity of the nipah virus attachment glycoprotein","volume":"25;375(6587):1373-1378","author":"Wang","year":"2022","journal-title":"Science"},{"issue":"30","key":"10.1016\/j.vaccine.2026.129113_bb0295","doi-asserted-by":"crossref","first-page":"10652","DOI":"10.1073\/pnas.0504887102","article-title":"Ephrin-B2 ligand is a functional receptor for hendra virus and nipah virus","volume":"102","author":"Bonaparte","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2026.129113_bb0300","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1128\/JVI.00999-07","article-title":"Single amino acid changes in the nipah and hendra virus attachment glycoproteins distinguish ephrinB2 from ephrinB3 usage","volume":"81","author":"Negrete","year":"2007","journal-title":"J Virol"},{"issue":"29","key":"10.1016\/j.vaccine.2026.129113_bb0305","doi-asserted-by":"crossref","first-page":"9953","DOI":"10.1073\/pnas.0804797105","article-title":"Host cell recognition by the henipaviruses: crystal structures of the nipah g attachment glycoprotein and its complex with ephrin-B3","volume":"105","author":"Xu","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0310","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.semcdb.2011.12.005","article-title":"Ephrin-B2 and ephrin-B3 as functional henipavirus receptors","volume":"23","author":"Xu","year":"2012","journal-title":"Semin Cell Dev Biol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129113_bb0315","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02427-14","article-title":"Heparan sulfate-dependent enhancement of henipavirus infection","volume":"6","author":"Mathieu","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2026.129113_bb0320","article-title":"Crystal structure of the pre-fusion nipah virus fusion glycoprotein reveals a novel Hexamer-of-Trimers assembly","volume":"8;11(12):e1005322","author":"Xu","year":"2015","journal-title":"PLoS Pathog"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129113_bb0325","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/v16020279","article-title":"Bivalent VSV vectors mediate rapid and potent protection from Andes virus challenge in hamsters","volume":"16","author":"Marceau","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.129113_bb0330","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.antiviral.2013.10.012","article-title":"Single-dose replication-defective VSV-based nipah virus vaccines provide protection from lethal challenge in Syrian hamsters","volume":"101","author":"Lo","year":"2014","journal-title":"Antiviral Res"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129113_bb0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002600","article-title":"Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus","volume":"7","author":"Mire","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"22","key":"10.1016\/j.vaccine.2026.129113_bb0340","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1016\/j.vaccine.2014.02.087","article-title":"Single-dose live-attenuated nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins","volume":"32","author":"DeBuysscher","year":"2014","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.vaccine.2026.129113_bb0345","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1016\/j.vaccine.2015.03.089","article-title":"Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects african green monkeys from nipah virus disease","volume":"33","author":"Prescott","year":"2015","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129113_bb0350","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2200065119","article-title":"A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal nipah virus disease","volume":"119","author":"Foster","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.vaccine.2026.129113_bb0355","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.3390\/v17081070","article-title":"Development and immunogenic evaluation of a recombinant vesicular stomatitis virus expressing nipah virus f and g glycoproteins","volume":"17","author":"Guo","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.129113_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104405","article-title":"Distinct VSV-based nipah virus vaccines expressing either glycoprotein g or fusion protein f provide homologous and heterologous protection in a nonhuman primate model","volume":"87","author":"de Wit","year":"2023","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129113_bb0365","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3201\/eid2505.181352","article-title":"Infections among contacts of patients with nipah virus, India","volume":"25","author":"Kumar","year":"2019","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129113_bb0370","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3201\/eid1110.050513","article-title":"Genetic characterization of nipah virus, Bangladesh, 2004","volume":"11","author":"Harcourt","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129113_bb0375","doi-asserted-by":"crossref","first-page":"16002","DOI":"10.1038\/npjvaccines.2016.2","article-title":"Peri-exposure protection against nipah virus disease using a single-dose recombinant vesicular stomatitis virus-based vaccine","volume":"1","author":"DeBuysscher","year":"2016","journal-title":"NPJ Vaccines."},{"key":"10.1016\/j.vaccine.2026.129113_bb0380","article-title":"A hendra virus g glycoprotein subunit vaccine protects african green monkeys from nipah virus challenge","volume":"4(146):146ra107","author":"Bossart","year":"2012","journal-title":"Sci Transl Med"},{"issue":"Suppl. 4","key":"10.1016\/j.vaccine.2026.129113_bb0385","doi-asserted-by":"crossref","first-page":"S471","DOI":"10.1093\/infdis\/jiz515","article-title":"A cross-reactive humanized monoclonal antibody targeting fusion glycoprotein function protects ferrets against lethal nipah virus and hendra virus infection","volume":"221","author":"Mire","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129113_bb0390","doi-asserted-by":"crossref","first-page":"1216225","DOI":"10.3389\/fimmu.2023.1216225","article-title":"Immunological correlates of protection afforded by PHV02 live, attenuated recombinant vesicular stomatitis virus vector vaccine against nipah virus disease","volume":"14","author":"Monath","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0395","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12910-021-00629-z","article-title":"Correction to: under consent: participation of people with HIV in an ebola vaccine trial in Canada","volume":"22","author":"David","year":"2021","journal-title":"BMC Med Ethics"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129113_bb0400","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010658","article-title":"Recombinant vesicular stomatitis vaccine against nipah virus has a favorable safety profile: model for assessment of live vaccines with neurotropic potential","volume":"18","author":"Monath","year":"2022","journal-title":"PLoS Pathog"},{"issue":"14","key":"10.1016\/j.vaccine.2026.129113_bb0405","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.129629","article-title":"Nipah virus persists in the brains of nonhuman primate survivors","volume":"4","author":"Liu","year":"2019","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129113_bb0410","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1079\/AHR200479","article-title":"Application of DIVA vaccines and their companion diagnostic tests to foreign animal disease eradication","volume":"5","author":"Pasick","year":"2004","journal-title":"Anim Health Res Rev"},{"key":"10.1016\/j.vaccine.2026.129113_bb0415","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/978-1-4939-3387-7_16","article-title":"Single-vector, single-injection recombinant vesicular stomatitis virus vaccines against high-containment viruses","volume":"1403","author":"Whitt","year":"2016","journal-title":"Methods Mol Biol"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129113_bb0420","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3201\/eid2506.181620","article-title":"Use of single-injection recombinant vesicular stomatitis virus vaccine to protect nonhuman primates against lethal nipah virus disease","volume":"25","author":"Mire","year":"2019","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129113_bb0425","first-page":"1980","volume":"15","author":"Pigeaud","year":"2023","journal-title":"Animal Models for Henipavirus Research. Viruses."},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0430","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41541-025-01343-2","article-title":"A single-cycle recombinant VSV vaccine displaying the hendra virus glycoprotein uniformly protects against hendra and nipah virus challenge","volume":"11","author":"Pigeaud","year":"2026","journal-title":"NPJ Vaccines."},{"issue":"8","key":"10.1016\/j.vaccine.2026.129113_bb0435","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01729-16","article-title":"Recombinant Isfahan virus and vesicular stomatitis virus vaccine vectors provide durable, multivalent, single-dose protection against lethal alphavirus challenge","volume":"91","author":"Nasar","year":"2017","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0440","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41541-022-00592-9","article-title":"ChAdOx1 NiV vaccination protects against lethal nipah Bangladesh virus infection in african green monkeys","volume":"7","author":"van Doremalen","year":"2022","journal-title":"NPJ Vaccines."},{"key":"10.1016\/j.vaccine.2026.129113_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-0716-3283-3_1","article-title":"Overview of experimental vaccines and antiviral therapeutics for henipavirus infection","volume":"2682","author":"Satterfield","year":"2023","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2026.129113_bb0450","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.772864","article-title":"Chimeric fusion (f) and attachment (g) glycoprotein antigen delivery by mRNA as a candidate nipah vaccine","volume":"12","author":"Loomis","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0455","doi-asserted-by":"crossref","first-page":"38367","DOI":"10.1038\/s41598-025-22282-x","article-title":"Negative-sense RNA virus nucleocapsid as a versatile platform for gene delivery, vaccine development, and antiviral screening","volume":"15","author":"Rehman","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.129113_bb0460","doi-asserted-by":"crossref","first-page":"1387811","DOI":"10.3389\/fimmu.2024.1387811","article-title":"A highly effective ferritin-based divalent nanoparticle vaccine shields Syrian hamsters against lethal nipah virus","volume":"15","author":"Yin","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.129113_bb0465","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41541-017-0023-7","article-title":"A VLP-based vaccine provides complete protection against nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model","volume":"2","author":"Walpita","year":"2017","journal-title":"NPJ Vaccines."},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb0470","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3201\/eid2003.131159","article-title":"Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health","volume":"20","author":"Middleton","year":"2014","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0475","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41541-021-00284-w","article-title":"A single dose investigational subunit vaccine for human use against nipah virus and hendra virus","volume":"6","author":"Geisbert","year":"2021","journal-title":"NPJ Vaccines."},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0480","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ajpath.2021.09.009","article-title":"Expanded histopathology and tropism of ebola virus in the rhesus macaque model: potential for sexual transmission, altered adrenomedullary hormone production, and early viral replication in liver","volume":"192","author":"Liu","year":"2022","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0485","doi-asserted-by":"crossref","first-page":"11043","DOI":"10.1038\/s41598-018-29401-x","article-title":"A VSV-based zika virus vaccine protects mice from lethal challenge","volume":"8","author":"Emanuel","year":"2018","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.vaccine.2026.129113_bb0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008602","article-title":"A complement component c1q-mediated mechanism of antibody-dependent enhancement of ebola virus infection","volume":"14","author":"Furuyama","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"18","key":"10.1016\/j.vaccine.2026.129113_bb0495","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa2501073","article-title":"Safety and immunogenicity of an rVSV Lassa fever vaccine candidate","volume":"393","author":"Malkin E, Zaric M, Kieh M, Baden LR, Fitz-Patrick D, Marini A, Yun H, Hayes P, Bromell R, Ayorinde M, Fernandez N, Varma R, Sigei F, Ward M, Pindolia H, Sewell S, Amini F, Blie J, Wilson B, Faley P, McCullough J, Tokpah F, Wisseh C, Towalid E, Hadawale S, Sayeed E, Hunt D, Keshavarzi N, Barin B, Maljkovic Berry I, Parks CL, Truter SG, Walker K, Vekemans J, Lehrman J, Engelbrecht M, Malherbe M, Laufer D, Philiponis V, Higgs E, Mutua G, Fast PE, Gupta SB; rVSV\u0394G-LASV-GPC Study Group","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0500","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41541-021-00416-2","article-title":"A live-attenuated viral vector vaccine protects mice against lethal challenge with kyasanur forest disease virus","volume":"6","author":"Bhatia","year":"2021","journal-title":"NPJ Vaccines."},{"issue":"9","key":"10.1016\/j.vaccine.2026.129113_bb0505","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3390\/vaccines10091446","article-title":"Lessons learned from the development and roll-out of the rVSV\u0394G-ZEBOV-GP Zaire ebolavirus vaccine to inform Marburg virus and Sudan ebolavirus vaccines","volume":"10","author":"Coller","year":"2022","journal-title":"Vaccines (Basel)."},{"issue":"52","key":"10.1016\/j.vaccine.2026.129113_bb0510","doi-asserted-by":"crossref","first-page":"6894","DOI":"10.1016\/j.vaccine.2008.09.082","article-title":"Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with ebola and Marburg viruses","volume":"26","author":"Geisbert","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129113_bb0515","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1093\/infdis\/jiv126","article-title":"A single-vector, single-injection trivalent filovirus vaccine: proof of concept study in outbred guinea pigs","volume":"212 Suppl 2(Suppl 2)","author":"Mire","year":"2015","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb0520","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.chom.2018.08.003","article-title":"Persistent Marburg virus infection in the testes of nonhuman primate survivors","volume":"24","author":"Coffin","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2026.129113_bb0525","series-title":"Hepatitis C viruses: Genomes and molecular biology","article-title":"Recombinant vesicular stomatitis virus (VSV) and other strategies in HCV vaccine designs and immunotherapy","author":"Majid","year":"2006"},{"issue":"16","key":"10.1016\/j.vaccine.2026.129113_bb0530","doi-asserted-by":"crossref","first-page":"8601","DOI":"10.1128\/JVI.00608-07","article-title":"Replication-competent recombinant vesicular stomatitis virus encoding hepatitis c virus envelope proteins","volume":"81","author":"Tani","year":"2007","journal-title":"J Virol"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2026.129113_bb0535","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tube.2006.01.017","article-title":"Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization","volume":"86","author":"Xing","year":"2006","journal-title":"Tuberculosis (Edinb)"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129113_bb0540","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.cell.2020.11.023","article-title":"Potent henipavirus neutralization by antibodies recognizing diverse sites on hendra and nipah virus receptor binding protein","volume":"183","author":"Dong","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0545","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-024-00814-2","article-title":"Single dose recombinant VSV based vaccine elicits robust and durable neutralizing antibody against hantaan virus","volume":"9","author":"Zhang","year":"2024","journal-title":"NPJ Vaccines."},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2026.129113_bb0550","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1086\/514306","article-title":"The reemergence of ebola hemorrhagic fever, Democratic Republic of the Congo, 1995","volume":"179","author":"Khan","year":"1999","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129113_bb0555","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/S2666-5247(20)30198-1","article-title":"Estimation of the correlates of protection of the rVSV\u0394G-ZEBOV-GP Zaire ebolavirus vaccine: A post-hoc analysis of data from phase 2\/3 clinical trials","volume":"2","author":"Grais","year":"2021","journal-title":"Lancet Microbe."},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0560","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1038\/s41598-023-29517-9","article-title":"Expanded profiling of remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro","volume":"13","author":"Radoshitzky","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.129113_bb0565","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/978-981-99-0113-5_18","article-title":"Replicating-competent VSV-vectored pseudotyped viruses","volume":"1407","author":"Yuan","year":"2023","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.vaccine.2026.129113_bb0570","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.595390","article-title":"Defective interfering genomes and the full-length viral genome trigger RIG-I after infection with vesicular stomatitis virus in a replication dependent manner","volume":"12","author":"Linder","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129113_bb0575","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/0092-8674(79)90337-4","article-title":"Defective interfering particles modulate VSV infection of dissociated neuron cultures","volume":"17","author":"Faulkner","year":"1979","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0580","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12985-021-01566-4","article-title":"The basic reproductive number and particle-to-plaque ratio: comparison of these two parameters of viral infectivity","volume":"18","author":"McCormick","year":"2021","journal-title":"Virol J"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129113_bb0585","doi-asserted-by":"crossref","first-page":"6466","DOI":"10.1128\/jvi.69.10.6466-6472.1995","article-title":"Vesicular stomatitis virus infection of the central nervous system activates both innate and acquired immunity","volume":"69","author":"Bi","year":"1995","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0590","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.virol.2006.10.026","article-title":"Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates","volume":"360","author":"Johnson","year":"2007","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0595","doi-asserted-by":"crossref","first-page":"10669","DOI":"10.1038\/s41598-018-28868-y","article-title":"Vesicular stomatitis virus g protein transmembrane region is crucial for the hemi-fusion to full fusion transition","volume":"8","author":"Ci","year":"2018","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129113_bb0600","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.vaccine.2011.12.085","article-title":"Evaluation of attenuated VSVs with mutated m or\/and g proteins as vaccine vectors","volume":"30","author":"Fang","year":"2012","journal-title":"Vaccine"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2026.129113_bb0605","doi-asserted-by":"crossref","first-page":"S226","DOI":"10.1093\/infdis\/jiv309","article-title":"RNA editing of the GP gene of ebola virus is an important pathogenicity factor","volume":"212","author":"Volchkova","year":"2015","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129113_bb0610","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3390\/v11110999","article-title":"The roles of ebola virus soluble glycoprotein in replication, pathogenesis, and countermeasure development","volume":"11","author":"Zhu","year":"2019","journal-title":"Viruses"},{"issue":"385","key":"10.1016\/j.vaccine.2026.129113_bb0615","doi-asserted-by":"crossref","first-page":"eaaj1701","DOI":"10.1126\/scitranslmed.aaj1701","article-title":"A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in europe and africa","volume":"9","author":"Huttner","year":"2017","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129113_bb0620","first-page":"e113","article-title":"Transcriptomic signatures induced by the ebola virus vaccine rVSV\u0394G-ZEBOV-GP in adult cohorts in europe, africa, and north america: A molecular biomarker study. Lancet","volume":"3","author":"Vianello E, Gonzalez-Dias P, van Veen S, Engele CG, Quinten E, Monath TP, Medaglini D; VSV-EBOVAC Consortium; VSV-EBOPLUS Consortium; Santoro F, Huttner A, Dubey S, Eichberg M, Ndungu FM, Kremsner PG, Essone PN, Agnandji ST, Siegrist CA, Nakaya HI, Ottenhoff THM, Haks MC","year":"2022","journal-title":"Microbe"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129113_bb0625","article-title":"Safety and immunogenicity of rVSV\u0394G-ZEBOV-GP ebola vaccine in adults and children in Lambar\u00e9n\u00e9, Gabon: A phase i randomised trial","volume":"14","author":"Agnandji ST, Fernandes JF, Bache EB, Obiang Mba RM, Brosnahan JS, Kabwende L, Pitzinger P, Staarink P, Massinga-Loembe M, Kr\u00e4hling V, Biedenkopf N, Fehling SK, Strecker T, Clark DJ, Staines HM, Hooper JW, Silvera P, Moorthy V, Kieny MP, Adegnika AA, Grobusch MP, Becker S, Ramharter M, Mordm\u00fcller B, Lell B; VEBCON Consortium; Krishna S, Kremsner PG","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2026.129113_bb0630","doi-asserted-by":"crossref","unstructured":"Lee AW, Liu K, Lhomme E, Blie J, McCullough J, Onorato MT, Connor L, Simon JK, Dubey S, VanRheenen S, Deutsch J, Owens A, Morgan A, Welebob C, Hyatt D, Nair S, Hamz\u00e9 B, Guindo O, Sow SO, Beavogui AH, Leigh B, Samai M, Akoo P, Serry-Bangura A, Fleck S, Secka F, Lowe B, Watson-Jones D, Roy C, Hensley LE, Kieh M, Coller BG; PREVAC Study Team. Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSV\u0394G-ZEBOV-GP Ebola Vaccine (ERVEBO\u00ae): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults. Clin Infect Dis. 2024;78(4):870-879.","DOI":"10.1093\/cid\/ciad693"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0635","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3390\/vaccines8010124","article-title":"Safety of administering live vaccines during pregnancy: A systematic review and Meta-analysis of pregnancy outcomes","volume":"8","author":"Laris-Gonz\u00e1lez","year":"2020","journal-title":"Vaccines (Basel)."},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2026.129113_bb0640","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1086\/514289","article-title":"Ebola hemorrhagic fever and pregnancy","volume":"179","author":"Mupapa","year":"1999","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129113_bb0645","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30194-8","article-title":"Pregnancy and breastfeeding in the context of ebola: A systematic review","volume":"20","author":"Foeller","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0650","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/vaccines8010038","article-title":"Being pregnant during the kivu ebola virus outbreak in DR Congo: the rVSV-ZEBOV vaccine and its accessibility by mothers and infants during humanitarian crises and in conflict areas","volume":"8","author":"Schwartz","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2026.129113_bb0655","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12978-017-0430-2","article-title":"Protected to death: systematic exclusion of pregnant women from ebola virus disease trials","volume":"14","author":"Gomes","year":"2017","journal-title":"Reprod Health"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129113_bb0660","first-page":"1370","article-title":"Being pregnant during the kivu ebola virus outbreak in the Democratic Republic of the Congo: the riskiest of times","volume":"12","author":"Schwartz","year":"2020","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb0665","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3201\/eid2603.191018","article-title":"Pregnancy outcomes among women receiving rVSV\u0394-ZEBOV-GP ebola vaccine during the Sierra Leone trial to introduce a vaccine against ebola","volume":"26","author":"Legardy-Williams","year":"2020","journal-title":"Emerg Infect Dis"},{"issue":"35","key":"10.1016\/j.vaccine.2026.129113_bb0670","doi-asserted-by":"crossref","first-page":"5159","DOI":"10.1016\/j.vaccine.2023.06.073","article-title":"Exclusion of pregnant people from emergency vaccine clinical trials: A systematic review of clinical trial protocols and reporting from 2009 to 2019","volume":"41","author":"Minchin","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129113_bb0675","doi-asserted-by":"crossref","unstructured":"Krubiner CB, Faden RR, Karron RA, Little MO, Lyerly AD, Abramson JS, Beigi RH, Cravioto AR, Durbin AP, Gellin BG, Gupta SB, Kaslow DC, Kochhar S, Luna F, Saenz C, Sheffield JS, Tindana PO; PREVENT Working Group. Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response. Vaccine 2021;39(1):85-120.","DOI":"10.1016\/j.vaccine.2019.01.011"},{"key":"10.1016\/j.vaccine.2026.129113_bb0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127513","article-title":"A template tool for the evaluation of vaccines for emerging pathogens to be used for pregnant and breast-feeding women","volume":"62","author":"Munoz","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129113_bb0685","series-title":"ERVEBO (Ebola Zaire vaccine, live)","author":"United States Food and Drug Administration","year":"2020"},{"issue":"8","key":"10.1016\/j.vaccine.2026.129113_bb0690","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01967-19","article-title":"Mucin-like domain of ebola virus glycoprotein enhances selective oncolytic actions against brain tumors","volume":"94","author":"Zhang","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.129113_bb0695","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/805629","article-title":"Systemic delivery of oncolytic viruses: hopes and hurdles","volume":"2012","author":"Ferguson","year":"2012","journal-title":"Adv Virol"},{"issue":"13","key":"10.1016\/j.vaccine.2026.129113_bb0700","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1158\/0008-5472.CAN-13-3306","article-title":"Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency","volume":"74","author":"Muik","year":"2014","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb0705","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/v10030108","article-title":"The oncolytic virus VSV-GP is effective against malignant melanoma","volume":"10","author":"Kimpel","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.129113_bb0710","doi-asserted-by":"crossref","unstructured":"Cook J, Peng KWW, Witzig TE, Broski SM, Villasboas JC, Paludo J, Patnaik MM, Rajkumar VV, Dispenzieri A, Leung N, Buadi F, Bennani NN, Ansell SM, Zhang L, Packiriswamy N, Balakrishnan B, Brunton B, Giers M, Ginos B, Dueck AC, Geyer S, Gertz MA, Warsame R, Go RS, Hayman SR, Dingli D, Kumar SK, Bergsagel PL, Munoz J, Gonsalves WI, Kourelis TV, Muchtar E, Kapoor P, Kyle RA, Lin Y, Siddiqui M, Fonder A, Hobbs M, Hwa YL, Naik S, Russell SJ, Lacy MQ. Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma. Blood Adv. 2022:bloodadvances.2021006631.","DOI":"10.1182\/bloodadvances.2021006631"},{"key":"10.1016\/j.vaccine.2026.129113_bb0715","doi-asserted-by":"crossref","first-page":"1085940","DOI":"10.3389\/fimmu.2023.1085940","article-title":"Preclinical efficacy of oncolytic VSV-IFN\u03b2 in treating cancer: A systematic review","volume":"14","author":"Moglan","year":"2023","journal-title":"Front Immunol"},{"issue":"24","key":"10.1016\/j.vaccine.2026.129113_bb0720","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.2217\/fon-2022-0439","article-title":"Phase i study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors","volume":"18","author":"Porosnicu","year":"2022","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129113_bb0725","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/dna.2023.0368","article-title":"Oncolytic therapy of solid tumors by modified vesicular stomatitis virus","volume":"43","author":"Gao","year":"2024","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.vaccine.2026.129113_bb0730","doi-asserted-by":"crossref","unstructured":"Samai M, Seward JF, Goldstein ST, Mahon BE, Lisk DR, Widdowson MA, Jalloh MI, Schrag SJ, Idriss A, Carter RJ, Dawson P, Kargbo SAS, Leigh B, Bawoh M, Legardy-Williams J, Deen G, Carr W, Callis A, Lindblad R, Russell JBW, Petrie CR, Fombah AE, Kargbo B, McDonald W, Jarrett OD, Walker RE, Gargiullo P, Bash-Taqi D, Gibson L, Fofanah AB, Schuchat A; STRIVE Study Team. The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSV\u2206G-ZEBOV-GP Vaccine Tolerability and Safety During the West Africa Ebola Outbreak. J Infect Dis. 2018;217(suppl_1):S6-S15. doi:https:\/\/doi.org\/10.1093\/infdis\/jiy020. Erratum in: J Infect Dis. 2018;218(3):508-507.","DOI":"10.1093\/infdis\/jiy020"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129113_bb0735","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027753","article-title":"Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: A prospective controlled cohort study","volume":"6","author":"Roukens","year":"2011","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129113_bb0740","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2532212123","article-title":"Type i IFN autoantibodies underlie chikungunya live-attenuated vaccine encephalitis","volume":"123","author":"Gervais","year":"2026","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129113_bb0745","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20202486","article-title":"Auto-antibodies to type i IFNs can underlie adverse reactions to yellow fever live attenuated vaccine","volume":"218","author":"Bastard","year":"2021","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb2115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12985-023-01989-1","article-title":"The detectable anti-interferon-\u03b3 autoantibodies in COVID-19 patients may be associated with disease severity","volume":"20","author":"Chen","year":"2023","journal-title":"Virol J"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129113_bb2120","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s10875-022-01252-2","article-title":"Early and rapid identification of COVID-19 patients with neutralizing type i interferon auto-antibodies","volume":"42","author":"Akbil","year":"2022","journal-title":"J Clin Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129113_bb0750","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s10096-023-04688-5","article-title":"Severe acute herpes virus type 2 primo-infection and its association with anti-type 1 interferon autoantibodies","volume":"42","author":"Martinot","year":"2023","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129113_bb0755","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1741-7015-11-94","article-title":"Age-related autoimmunity","volume":"11","author":"Vadasz","year":"2013","journal-title":"BMC Med"},{"issue":"7902","key":"10.1016\/j.vaccine.2026.129113_bb0760","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41586-022-04447-0","article-title":"Human genetic and immunological determinants of critical COVID-19 pneumonia","volume":"603","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.129113_bb0765","doi-asserted-by":"crossref","first-page":"S1090","DOI":"10.1093\/infdis\/jir379","article-title":"Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal ebola virus infection","volume":"204 Suppl 3(Suppl 3)","author":"Tsuda","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129113_bb0770","doi-asserted-by":"crossref","unstructured":"Fletcher P, O'Donnell KL, Feldmann F, Rhoderick JF, Clancy CS, Prator CA, Smith BJ, Gunn BM, Feldmann H, Marzi A. Single-dose VSV-Sudan virus vaccine protects from lethal Sudan virus infection within one week: a challenge study in macaques: VSV-SUDV but not VSV-EBOV protects NHPs from Sudan virus disease. bioRxiv [Preprint]. 2025:2025.03.26.645555.","DOI":"10.1101\/2025.03.26.645555"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129113_bb0775","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1099\/jgv.0.001329","article-title":"Comparative evaluation of pathogenicity of three isolates of vesicular stomatitis virus (Indiana serotype) in pigs","volume":"100","author":"Morozov","year":"2019","journal-title":"J Gen Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0780","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/22221751.2021.1903343","article-title":"High dose of vesicular stomatitis virus-vectored ebola virus vaccine causes vesicular disease in swine without horizontal transmission","volume":"10","author":"Morozov","year":"2021","journal-title":"Emerg Microbes Infect"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129113_bb0785","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3201\/eid2104.142012","article-title":"Safety of recombinant VSV-Ebola virus vaccine vector in pigs","volume":"21","author":"de Wit","year":"2015","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb0790","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001567","article-title":"Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates","volume":"6","author":"Mire","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129113_bb0795","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/vaccines8040779","article-title":"Environmental risk assessment for rVSV\u0394G-ZEBOV-GP, a genetically modified live vaccine for ebola virus disease","volume":"8","author":"Tell","year":"2020","journal-title":"Vaccines (Basel)."},{"issue":"15","key":"10.1016\/j.vaccine.2026.129113_bb0800","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1073\/pnas.0500729102","article-title":"On the conservative nature of intragenic recombination","volume":"102","author":"Drummond","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129113_bb0805","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/hs.2023.0007","article-title":"Chimeric viruses containing select agents: the biology behind their creation, attenuation, and exclusion from regulation","volume":"21","author":"Wells","year":"2023","journal-title":"Health Secur"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129113_bb0810","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1128\/JVI.02675-13","article-title":"Quantitative characterization of defective virus emergence by deep sequencing","volume":"88","author":"Timm","year":"2014","journal-title":"J Virol"},{"issue":"45","key":"10.1016\/j.vaccine.2026.129113_bb0815","doi-asserted-by":"crossref","first-page":"7166","DOI":"10.1016\/j.vaccine.2020.08.001","article-title":"Characterization of rVSV\u0394G-ZEBOV-GP glycoproteins using automated capillary western blotting","volume":"38","author":"Minsker","year":"2020","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129113_bb0820","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1006\/viro.2001.1058","article-title":"Mechanisms of loss of foreign gene expression in recombinant vesicular stomatitis viruses","volume":"287","author":"Qui\u00f1ones-Kochs","year":"2001","journal-title":"Virology"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2026.129113_bb0825","doi-asserted-by":"crossref","first-page":"S404","DOI":"10.1086\/520591","article-title":"Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of ebola virus hemorrhagic fever","volume":"196","author":"Jones","year":"2007","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129113_bb0830","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV ebola candidate vaccine: A randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, Kaya G, Kr\u00e4hling V, Kwilas S, Lema\u00eetre B, Matthey A, Silvera P, Becker S, Fast PE, Moorthy V, Kieny MP, Kaiser L, Siegrist CA; VSV-Ebola Consortium","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"17","key":"10.1016\/j.vaccine.2026.129113_bb0835","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV ebola vaccine in africa and europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.vaccine.2026.129113_bb0840","doi-asserted-by":"crossref","first-page":"E819","DOI":"10.1503\/cmaj.170074","article-title":"Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus ebola vaccine in healthy adults: A randomized clinical trial","volume":"189","author":"ElSherif MS, Brown C, MacKinnon-Cameron D, Li L, Racine T, Alimonti J, Rudge TL, Sabourin C, Silvera P, Hooper JW, Kwilas SA, Kilgore N, Badorrek C, Ramsey WJ, Heppner DG, Kemp T, Monath TP, Nowak T, McNeil SA, Langley JM, Halperin SA; Canadian Immunization Research Network","year":"2017","journal-title":"CMAJ"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129113_bb0845","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus ebola vaccine","volume":"376","author":"Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Mu\u00f1oz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Guti\u00e9rrez RL, Remich SA, Hack HR, Wisniewski ML, Josleyn MD, Kwilas SA, Van Deusen N, Mbaya OT, Zhou Y, Stanley DA, Jing W, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peel SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey RT Jr, Thomas SJ; rVSV\u0394G-ZEBOV-GP Study Group","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.vaccine.2026.129113_bb0850","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S1473-3099(17)30313-4","article-title":"V920-004 study team. Safety and immunogenicity of the rVSV\u2206G-ZEBOV-GP ebola virus vaccine candidate in healthy adults: A phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study","volume":"17","author":"Heppner","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129113_bb0855","article-title":"Replication, safety and immunogenicity of the vectored ebola vaccine rVSV-DG-ZEBOV-GP in a sub-Saharan african pediatric population: A randomised controlled, open-label trial in children aged 1-12 years living in Lambar\u00e9n\u00e9","volume":"89","author":"Alabi","year":"2024","journal-title":"Gabon J Infect"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129113_bb0860","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1080\/21645515.2017.1412898","article-title":"Assessment of the ability of v920 recombinant vesicular stomatitis-Zaire ebolavirus vaccine to replicate in relevant arthropod cell cultures and vector species","volume":"14","author":"Bergren","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb0865","first-page":"1093","article-title":"No evidence of rVSV-Ebola virus vaccine replication or dissemination in the sand fly phlebotomus papatasi","volume":"104","author":"Haddow","year":"2021","journal-title":"Am J Trop Med Hyg"},{"issue":"8","key":"10.1016\/j.vaccine.2026.129113_bb0870","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1021\/acsinfecdis.0c00018","article-title":"Examining the role of Niemann-pick c1 protein in the permissiveness of aedes mosquitoes to filoviruses","volume":"6","author":"Gold","year":"2020","journal-title":"ACS Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129113_bb0875","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.4269\/ajtmh.22-0323","article-title":"Limited capacity for aedes aegypti to mechanically transmit chikungunya virus and dengue virus","volume":"107","author":"Bransfield","year":"2022","journal-title":"Am J Trop Med Hyg"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129113_bb0880","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/infdis\/160.6.970","article-title":"Potential for insect transmission of HIV: experimental exposure of cimex hemipterus and toxorhynchites amboinensis to human immunodeficiency virus","volume":"160","author":"Webb","year":"1989","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb0885","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/WCO.0000000000001154","article-title":"Chronic and delayed neurological manifestations of persistent infections","volume":"36","author":"Pandya","year":"2023","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb2125","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/s42003-022-04158-2","article-title":"Persistent intraocular ebola virus RNA is associated with severe uveitis in a convalescent rhesus monkey","volume":"5","author":"Worwa","year":"2022","journal-title":"Commun Biol"},{"issue":"Suppl. 7","key":"10.1016\/j.vaccine.2026.129113_bb0890","doi-asserted-by":"crossref","first-page":"S554","DOI":"10.1093\/infdis\/jiad118","article-title":"Establishing a mouse model for sexual transmission and male reproductive tract persistence of ebola virus","volume":"228","author":"Clancy","year":"2023","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb0895","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012065","article-title":"Ebola virus disease sequelae and viral persistence in animal models: implications for the future","volume":"20","author":"Durant","year":"2024","journal-title":"PLoS Pathog"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129113_bb0900","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1016\/S1473-3099(16)00077-3","article-title":"Sequelae of ebola virus disease: the emergency within the emergency","volume":"16","author":"Vetter","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129113_bb0905","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijid.2015.12.011","article-title":"Recurrence and reinfection-a new paradigm for the management of ebola virus disease","volume":"43","author":"MacIntyre","year":"2016","journal-title":"Int J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129113_bb0910","article-title":"Fatal meningoencephalitis associated with ebola virus persistence in two survivors of ebola virus disease in the Democratic Republic of the Congo: A case report study. Lancet","volume":"5","author":"Mukadi-Bamuleka D, Edidi-Atani F, Morales-Betoulle ME, Legand A, Nkuba-Ndaye A, Bulabula-Penge J, Mbala-Kingebeni P, Crozier I, Mambu-Mbika F, Whitmer S, Tshiani Mbaya O, Hensley LE, Kitenge-Omasumbu R, Davey R, Mulangu S, Fonjungo PN, Wiley MR, Klena JD, Peeters M, Delaporte E, van Griensven J, Ari\u00ebn KK, Pratt C, Montgomery JM, Formenty P, Muyembe-Tamfum JJ, Ahuka-Mundeke S; EBOV Persistence Study Group","year":"2024","journal-title":"Microbe"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129113_bb0915","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3390\/v10120683","article-title":"Persistence and sexual transmission of filoviruses","volume":"10","author":"Schindell","year":"2018","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129113_bb0920","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1006\/viro.1996.0271","article-title":"Persistence of vesicular stomatitis virus new Jersey RNA in convalescent hamsters","volume":"219","author":"Barrera","year":"1996","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129113_bb0925","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1006\/viro.1996.0275","article-title":"Vesicular stomatitis new Jersey virus RNA persists in cattle following convalescence","volume":"219","author":"Letchworth","year":"1996","journal-title":"Virology"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129113_bb0930","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1017\/S0950268811000550","article-title":"Evidence for nipah virus recrudescence and serological patterns of captive pteropus vampyrus","volume":"139","author":"Sohayati AR, Hassan L, Sharifah SH, Lazarus K, Zaini CM, Epstein JH, Shamsyul Naim N, Field HE, Arshad SS, Abdul Aziz J, Daszak P; Henipavirus Ecology Research Group","year":"2011","journal-title":"Epidemiol Infect"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0935","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41467-024-45231-0","article-title":"Selective replication and vertical transmission of ebola virus in experimentally infected angolan free-tailed bats","volume":"15","author":"Riesle-Sbarbaro","year":"2024","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129113_bb0940","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/v12020151","article-title":"Replication compartments of DNA viruses in the nucleus: location, location, location","volume":"12","author":"Charman","year":"2020","journal-title":"Viruses"},{"issue":"8","key":"10.1016\/j.vaccine.2026.129113_bb0945","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a039446","article-title":"Viruses in the nucleus","volume":"13","author":"Lucic","year":"2021","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.vaccine.2026.129113_bb0950","first-page":"143","article-title":"Plant rhabdoviruses","volume":"292","author":"Redinbaugh","year":"2005","journal-title":"Curr Top Microbiol Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2026.129113_bb0955","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1089\/jir.2009.0068","article-title":"Rhabdovirus evasion of the interferon system","volume":"29","author":"Rieder","year":"2009","journal-title":"J Interferon Cytokine Res"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0960","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/187152612798994966","article-title":"Subcellular trafficking in rhabdovirus infection and immune evasion: A novel target for therapeutics","volume":"12","author":"Oksayan","year":"2012","journal-title":"Infect Disord Drug Targets"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129113_bb0965","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.3390\/v5071824","article-title":"Nuclear imprisonment: viral strategies to arrest host mRNA nuclear export","volume":"5","author":"Kuss","year":"2013","journal-title":"Viruses"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129113_bb0970","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/embor.2009.179","article-title":"Vesicular stomatitis virus inhibits mitotic progression and triggers cell death","volume":"10","author":"Chakraborty","year":"2009","journal-title":"EMBO Rep"},{"issue":"21","key":"10.1016\/j.vaccine.2026.129113_bb0975","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2105968118","article-title":"Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb0980","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-virology-092818-015613","article-title":"The potential role of endogenous viral elements in the evolution of bats as reservoirs for zoonotic viruses","volume":"7","author":"Skirmuntt","year":"2020","journal-title":"Annu Rev Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129113_bb0985","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1007\/s00204-024-03746-x","article-title":"Genotoxicity and safety pharmacology of the rVSVInd(GML)-mspSGtc vaccine against SARS-CoV-2 in Sprague-Dawley rats and beagle dogs","volume":"98","author":"Park","year":"2024","journal-title":"Arch Toxicol"},{"issue":"46","key":"10.1016\/j.vaccine.2026.129113_bb0990","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1016\/j.vaccine.2022.09.037","article-title":"Immunogenicity of rVSV\u0394G-ZEBOV-GP ebola vaccine (ERVEBO\u00ae) in african clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three phase 2\/3 trials","volume":"40","author":"Simon","year":"2022","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.vaccine.2026.129113_bb0995","doi-asserted-by":"crossref","first-page":"360","DOI":"10.15585\/mmwr.mm7316a1","article-title":"Use of ebola vaccines - worldwide, 2021-2023","volume":"73","author":"Kallay","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2026.129113_bb1000","unstructured":"World Health Organization \/ Democratic Republic of the Congo Ministry of Health. Ebola virus disease - Democratic Republic of the Congo. Situation Report 2020. Geneva: WHO; 2020. [Note: please verify exact report date and replace with full citation]."},{"key":"10.1016\/j.vaccine.2026.129113_bb1005","article-title":"Prevac study team. Long-term cellular immunity of vaccines for Zaire ebola virus diseases","volume":"15(1):7666","author":"Wiedemann","year":"2024","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.vaccine.2026.129113_bb1010","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-102898","article-title":"Safety and immunogenicity of rVSV\u0394G-ZEBOV-GP vaccination when dosed concurrent with mRNA COVID-19 vaccine booster doses in healthy african adults (EbolaCov): protocol for a phase IV, single-Centre, single-blinded, randomised controlled trial","volume":"15","author":"Gokani","year":"2025","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129113_bb1015","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1128\/JVI.01621-12","article-title":"Filoviruses utilize glycosaminoglycans for their attachment to target cells","volume":"87","author":"Salvador","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.129113_bb1020","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3390\/v3081501","article-title":"Intracellular events and cell fate in filovirus infection","volume":"3","author":"Olejnik","year":"2011","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb1025","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1128\/JVI.75.3.1576-1580.2001","article-title":"Ebola virus glycoprotein: Proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies","volume":"75","author":"Ito","year":"2001","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129113_bb1030","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/path.4456","article-title":"Tissue and cellular tropism, pathology and pathogenesis of ebola and Marburg viruses","volume":"235","author":"Martines","year":"2015","journal-title":"J Pathol"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129113_bb1035","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-104843","article-title":"SMILE and EVICT-VR investigator study groups. Understanding the pathogenesis of uveitis in ebola virus disease survivors: an observational cohort and cross-sectional study protocol for clinical, molecular virologic and immunologic characterisation","volume":"15","author":"Hartley","year":"2025","journal-title":"BMJ Open"},{"issue":"Suppl. 7","key":"10.1016\/j.vaccine.2026.129113_bb1040","doi-asserted-by":"crossref","first-page":"S626","DOI":"10.1093\/infdis\/jiad239","article-title":"Ebola virus tropism in ex vivo cynomolgus macaque ocular tissues","volume":"228","author":"Matson","year":"2023","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb1045","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1128\/CVI.00733-14","article-title":"Next-generation sequencing reveals a controlled immune response to Zaire ebola virus challenge in cynomolgus macaques immunized with vesicular stomatitis virus expressing Zaire ebola virus glycoprotein (VSV\u0394G\/EBOVgp)","volume":"22","author":"Barrenas","year":"2015","journal-title":"Clin Vaccine Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb1050","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00597-19","article-title":"Antiviral innate responses induced by VSV-EBOV vaccination contribute to rapid protection","volume":"10","author":"Menicucci","year":"2019","journal-title":"mBio"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129113_bb1055","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3201\/eid2102.141649","article-title":"Vesicular stomatitis virus-based vaccines against Lassa and ebola viruses","volume":"21","author":"Marzi","year":"2015","journal-title":"Emerg Infect Dis"},{"issue":"Suppl. 7","key":"10.1016\/j.vaccine.2026.129113_bb1060","doi-asserted-by":"crossref","first-page":"S721","DOI":"10.1093\/infdis\/jiad280","article-title":"Limited benefit of postexposure prophylaxis with VSV-EBOV in ebola virus-infected rhesus macaques","volume":"228","author":"Bushmaker","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129113_bb1065","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ebiom.2017.03.045","article-title":"VEBCON Consortium. Dose-dependent t-cell dynamics and cytokine cascade following rVSV-ZEBOV immunization","volume":"19","author":"Dahlke","year":"2017","journal-title":"EBioMedicine"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129113_bb1070","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129113_bb1075","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal ebola virus challenge in nonhuman primates","volume":"110","author":"Marzi","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.vaccine.2026.129113_bb1080","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.vaccine.2023.01.059","article-title":"Cellular and humoral immunity to ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based ebola vaccine (rVSV\u0394G-ZEBOV-GP)","volume":"41","author":"Raabe","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129113_bb1085","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ebiom.2019.09.055","article-title":"Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal ebola challenge","volume":"49","author":"Marzi","year":"2019","journal-title":"EBioMedicine"},{"issue":"158","key":"10.1016\/j.vaccine.2026.129113_bb1090","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004582","article-title":"Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates","volume":"4","author":"Wong","year":"2012","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129113_bb1095","doi-asserted-by":"crossref","DOI":"10.1093\/femspd\/ftw021","article-title":"Cell-targeting antibodies in immunity to ebola","volume":"74","author":"Schmaljohn","year":"2016","journal-title":"Pathog Dis"},{"issue":"31","key":"10.1016\/j.vaccine.2026.129113_bb1100","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1016\/j.vaccine.2020.04.061","article-title":"Serostatus cutoff levels and fold increase to define seroresponse to recombinant vesicular stomatitis virus - Zaire ebola virus envelope glycoprotein vaccine: an evidence-based analysis","volume":"38","author":"Antonello","year":"2020","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129113_bb1105","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e11676","article-title":"Longitudinal antibody titer, avidity, and neutralizing responses after SARS-CoV-2 infection","volume":"8","author":"Monroe","year":"2022","journal-title":"Heliyon"},{"issue":"8","key":"10.1016\/j.vaccine.2026.129113_bb1110","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.immuni.2021.07.008","article-title":"Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations","volume":"54","author":"Muecksch","year":"2021","journal-title":"Immunity"},{"issue":"7851","key":"10.1016\/j.vaccine.2026.129113_bb1115","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","article-title":"Evolution of antibody immunity to SARS-CoV-2","volume":"591","author":"Gaebler","year":"2021","journal-title":"Nature"},{"issue":"602","key":"10.1016\/j.vaccine.2026.129113_bb1120","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg6128","article-title":"Ebola vaccine-induced protection in nonhuman primates correlates with antibody specificity and fc-mediated effects","volume":"13","author":"Meyer","year":"2021","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129113_bb1125","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/s41590-018-0233-9","article-title":"Antibody-mediated protection against ebola virus","volume":"19","author":"Saphire","year":"2018","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129113_bb1130","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1128\/JVI.75.5.2324-2330.2001","article-title":"Infectivity-enhancing antibodies to ebola virus glycoprotein","volume":"75","author":"Takada","year":"2001","journal-title":"J Virol"},{"issue":"13","key":"10.1016\/j.vaccine.2026.129113_bb1135","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1128\/JVI.77.13.7539-7544.2003","article-title":"Antibody-dependent enhancement of ebola virus infection","volume":"77","author":"Takada","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.129113_bb1140","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.molimm.2022.11.010","article-title":"Antibody-dependent enhancement (ADE) and the role of complement system in disease pathogenesis","volume":"152","author":"Thomas","year":"2022","journal-title":"Mol Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129113_bb1145","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.celrep.2018.07.035","article-title":"Antibody-dependent enhancement of ebola virus infection by human antibodies isolated from survivors","volume":"24","author":"Kuzmina","year":"2018","journal-title":"Cell Rep"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129113_bb1150","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1473-3099(18)30165-8","article-title":"Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for ebola virus disease: an observational cohort study","volume":"18","author":"Huttner","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"21","key":"10.1016\/j.vaccine.2026.129113_bb1155","doi-asserted-by":"crossref","first-page":"11359","DOI":"10.1073\/pnas.93.21.11359","article-title":"Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles","volume":"93","author":"Schnell","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2026.129113_bb1160","doi-asserted-by":"crossref","first-page":"S1066","DOI":"10.1093\/infdis\/jir348","article-title":"Vesicular stomatitis virus-based ebola vaccines with improved cross-protective efficacy","volume":"204","author":"Marzi","year":"2011","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2026.129113_bb1165","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00975-25","article-title":"A versatile H5N1-VSV platform for safe influenza virus research applications","volume":"99","author":"Sownthirarajan","year":"2025","journal-title":"J Virol"},{"issue":"14","key":"10.1016\/j.vaccine.2026.129113_bb1170","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1128\/JVI.00561-09","article-title":"Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of ebola virus","volume":"83","author":"Geisbert","year":"2009","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129113_bb1175","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1128\/JVI.01911-06","article-title":"Synergistic attenuation of vesicular stomatitis virus by combination of specific g gene truncations and n gene translocations","volume":"81","author":"Clarke","year":"2007","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb1180","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1128\/JVI.01515-07","article-title":"Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice","volume":"82","author":"Cooper","year":"2008","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb1185","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01190-17","article-title":"Single-dose trivalent VesiculoVax vaccine protects macaques from lethal ebolavirus and marburgvirus challenge","volume":"92","author":"Matassov","year":"2018","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb1190","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1172\/JCI131958","article-title":"Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death","volume":"130","author":"Cross","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2026.129113_bb1195","doi-asserted-by":"crossref","first-page":"S1075","DOI":"10.1093\/infdis\/jir349","article-title":"Recombinant vesicular stomatitis virus-based vaccines against ebola and Marburg virus infections","volume":"204 Suppl 3(Suppl 3)","author":"Geisbert","year":"2011","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129113_bb1200","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3390\/pathogens10070816","article-title":"Impacts of infectious dose, feeding behavior, and age of culicoides sonorensis biting midges on infection dynamics of vesicular stomatitis virus","volume":"10","author":"Rozo-Lopez","year":"2021","journal-title":"Pathogens"},{"issue":"22","key":"10.1016\/j.vaccine.2026.129113_bb1205","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1016\/j.vaccine.2009.03.006","article-title":"In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 gag following intramuscular, intranasal, or intravenous inoculation","volume":"27","author":"Johnson","year":"2009","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb1210","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00204-021-03214-w","article-title":"Preliminary nonclinical safety and immunogenicity of an rVSV-\u0394G-SARS-CoV-2-S vaccine in mice, hamsters, rabbits and pigs","volume":"96","author":"Madar-Balakirski","year":"2022","journal-title":"Arch Toxicol"},{"issue":"8","key":"10.1016\/j.vaccine.2026.129113_bb1215","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00204-022-03302-5","article-title":"RVSV-\u0394G-SARS-CoV-2-S vaccine: repeated intramuscular (IM) toxicity, local tolerance, immunogenicity and biodistribution study in NZW rabbits","volume":"96","author":"Rosner","year":"2022","journal-title":"Arch Toxicol"},{"issue":"8","key":"10.1016\/j.vaccine.2026.129113_bb1220","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3390\/vaccines12080858","article-title":"Preclinical safety assessment of the EBS-LASV vaccine candidate against Lassa fever virus","volume":"12","author":"Matassov","year":"2024","journal-title":"Vaccines (Basel)."},{"issue":"8","key":"10.1016\/j.vaccine.2026.129113_bb1225","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/cid\/ciw469","article-title":"Ebola virus-related encephalitis","volume":"63","author":"de Greslan","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129113_bb1230","article-title":"Therapeutic treatment of nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody","volume":"6(242):242ra82","author":"Geisbert","year":"2014","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb1235","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.vaccine.2022.12.029","article-title":"Neurovirulence, viscerotropism and immunogenicity of live attenuated yellow fever 17D vaccine virus in non-human primates","volume":"41","author":"Tyagi","year":"2023","journal-title":"Vaccine"},{"issue":"28","key":"10.1016\/j.vaccine.2026.129113_bb1240","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1016\/j.vaccine.2011.04.055","article-title":"Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review","volume":"29","author":"Thomas","year":"2011","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129113_bb1245","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taw045","article-title":"Adverse event reports following yellow fever vaccination, 2007-13","volume":"23","author":"Lindsey","year":"2016","journal-title":"J Travel Med"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129113_bb1250","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taad160","article-title":"Yellow fever vaccine-associated neurologic and viscerotropic disease: A 10-year case series of the french national reference center for arboviruses with clinical and immunological insights","volume":"31","author":"Le Hir","year":"2024","journal-title":"J Travel Med"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb1255","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/humc.2016.061","article-title":"Safety studies in tumor and non-tumor-bearing mice in support of clinical trials using oncolytic VSV-IFN\u03b2-NIS","volume":"27","author":"Zhang","year":"2016","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.vaccine.2026.129113_bb1260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2014.09.001","article-title":"Clinical features and pathobiology of ebolavirus infection","volume":"55","author":"Ansari","year":"2014","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb1265","doi-asserted-by":"crossref","first-page":"2477300","DOI":"10.1080\/07853890.2025.2477300","article-title":"Age-related changes in the immune system and challenges for the development of age-specific vaccines","volume":"57","author":"Doherty","year":"2025","journal-title":"Ann Med"},{"key":"10.1016\/j.vaccine.2026.129113_bb1270","doi-asserted-by":"crossref","unstructured":"Fernbach S, Mair NK, Abela IA, Groen K, Kuratli R, Lork M, Thorball CW, Bernasconi E, Filippidis P, Leuzinger K, Notter J, Rauch A, Hirsch HH, Huber M, G\u00fcnthard HF, Fellay J, Kouyos RD, Hale BG; Swiss HIV Cohort Study. Longitudinal analysis over decades reveals the development and immune implications of type i interferon autoantibodies in an aging population. Health & Medicine Week, 22; 2024, p. 2727.","DOI":"10.1101\/2024.02.27.24303363"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb1275","first-page":"253","article-title":"Animal models of ebolavirus infection","volume":"67","author":"St Claire","year":"2017","journal-title":"Comp Med"},{"issue":"9","key":"10.1016\/j.vaccine.2026.129113_bb1280","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1080\/21645515.2018.1473698","article-title":"The vesicular stomatitis virus-based ebola virus vaccine: from concept to clinical trials","volume":"14","author":"Suder","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.129113_bb1285","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3389\/fmicb.2013.00267","article-title":"Animal models for ebola and Marburg virus infections","volume":"4","author":"Nakayama","year":"2013","journal-title":"Front Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129113_bb1290","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/infdis\/jis626","article-title":"A Syrian golden hamster model recapitulating ebola hemorrhagic fever","volume":"207","author":"Ebihara","year":"2013","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb1295","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/ilar\/ilab011","article-title":"The ferret as a model for filovirus pathogenesis and countermeasure evaluation","volume":"61","author":"Schiffman","year":"2022","journal-title":"ILAR J"},{"key":"10.1016\/j.vaccine.2026.129113_bb1300","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.1016\/j.vaccine.2014.08.028","article-title":"Immunization with vesicular stomatitis virus vaccine expressing the ebola glycoprotein provides sustained long-term protection in rodents","volume":"32","author":"Wong","year":"2014","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129113_bb1305","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00250-20","article-title":"Early transcriptional changes within liver, adrenal gland, and lymphoid tissues significantly contribute to ebola virus pathogenesis in cynomolgus macaques","volume":"94","author":"Jankeel","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.129113_bb1310","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.coviro.2017.03.001","article-title":"Within host RNA virus persistence: mechanisms and consequences","volume":"23","author":"Randall","year":"2017","journal-title":"Curr Opin Virol"},{"issue":"7877","key":"10.1016\/j.vaccine.2026.129113_bb1315","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41586-021-03901-9","article-title":"Resurgence of ebola virus in 2021 in guinea suggests a new paradigm for outbreaks","volume":"597","author":"Keita","year":"2021","journal-title":"Nature"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2026.129113_bb1320","doi-asserted-by":"crossref","first-page":"S248","DOI":"10.1086\/514292","article-title":"A mouse model for evaluation of prophylaxis and therapy of ebola hemorrhagic fever","volume":"179","author":"Bray","year":"1999","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb1325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.0030002","article-title":"Effective post-exposure treatment of ebola infection","volume":"3","author":"Feldmann","year":"2007","journal-title":"PLoS Pathog"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb1330","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41541-023-00685-z","article-title":"The rVSV-EBOV vaccine provides limited cross-protection against Sudan virus in guinea pigs","volume":"8","author":"Cao","year":"2023","journal-title":"NPJ Vaccines."},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb1335","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.cell.2015.12.022","article-title":"Cross-reactive and potent neutralizing antibody responses in human survivors of natural ebolavirus infection","volume":"164","author":"Flyak","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2026.129113_bb1340","doi-asserted-by":"crossref","unstructured":"Bente D, Gren J, Strong JE, Feldmann H. Disease modeling for ebola and Marburg viruses. Dis Model Mech 2009;2(1-2):12-17.-17.","DOI":"10.1242\/dmm.000471"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129113_bb1345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005547","article-title":"Mucosal immunization of cynomolgus macaques with the VSVDeltaG\/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses","volume":"4","author":"Qiu","year":"2009","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb1350","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3390\/v17030341","article-title":"RVSV\u0394G-ZEBOV-GP vaccine is highly immunogenic and efficacious across a wide dose range in a nonhuman primate EBOV challenge model","volume":"17","author":"Shurtleff","year":"2025","journal-title":"Viruses"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2026.129113_bb1355","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.1093\/infdis\/jiw218","article-title":"Efficacy of vesicular stomatitis virus-Ebola virus postexposure treatment in rhesus macaques infected with ebola virus makona","volume":"214","author":"Marzi","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129113_bb1360","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.coviro.2021.10.007","article-title":"Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity","volume":"51","author":"Pinski","year":"2021","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2026.129113_bb1365","doi-asserted-by":"crossref","unstructured":"Marzi A, Robertson SJ, Haddock E, Feldmann F, Hanley PW, Scott DP, Strong JE, Kobinger G, Best SM, Feldmann H. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014\/15 ebola virus outbreak strain. Science 2015;349(6249):739-42.","DOI":"10.1126\/science.aab3920"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb1370","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3390\/v17030342","article-title":"Durability of immunogenicity and protection of rVSV\u2206G-ZEBOV-GP vaccine in a nonhuman primate EBOV challenge model","volume":"17","author":"Bixler","year":"2025","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129113_bb1375","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3201\/eid1607.100159","article-title":"Postexposure treatment of Marburg virus infection","volume":"16","author":"Geisbert","year":"2010","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129113_bb1380","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.chom.2020.01.001","article-title":"Longitudinal human antibody repertoire against complete viral proteome from ebola virus survivor reveals protective sites for vaccine design","volume":"27","author":"Khurana","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb1385","doi-asserted-by":"crossref","first-page":"21390","DOI":"10.1038\/s41598-023-48397-7","article-title":"Effectiveness of VSV vectored SARS-CoV-2 spike when administered through intranasal, intramuscular or a combination of both","volume":"13","author":"Beitari","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.129113_bb1390","article-title":"Evaluation of waning of IgG antibody responses after rVSV\u0394G-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-filo ebola virus disease vaccines: A modelling study from the PREVAC randomized trial. Emerg","volume":"14(1):0","author":"Valayer","year":"2025","journal-title":"Microbes Infect"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb1395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/mi.2014.114","article-title":"Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings","volume":"8","author":"Clarke","year":"2015","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2026.129113_bb1400","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.596166","article-title":"Viral infections, the microbiome, and probiotics","volume":"10","author":"Harper","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129113_bb1405","doi-asserted-by":"crossref","first-page":"e787","DOI":"10.1016\/S2666-5247(22)00185-9","article-title":"The early-life gut microbiome and vaccine efficacy","volume":"3","author":"Jordan","year":"2022","journal-title":"Lancet Microbe."},{"issue":"10","key":"10.1016\/j.vaccine.2026.129113_bb1410","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/s41591-019-0602-4","article-title":"Polyclonal and convergent antibody response to ebola virus vaccine rVSV-ZEBOV","volume":"25","author":"Ehrhardt","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.129113_bb1415","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.706757","article-title":"Proteo-genomic analysis identifies two major sites of vulnerability on ebolavirus glycoprotein for neutralizing antibodies in convalescent human plasma","volume":"12","author":"Gilchuk","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129113_bb1420","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3390\/vaccines11050977","article-title":"Optimal expression, function, and immunogenicity of an HIV-1 vaccine derived from the approved ebola vaccine, rVSV-ZEBOV","volume":"11","author":"Azizi","year":"2023","journal-title":"Vaccines (Basel)."},{"issue":"15","key":"10.1016\/j.vaccine.2026.129113_bb1425","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMoa1614067","article-title":"Lane HC; PREVAIL i study group. Phase 2 placebo-controlled trial of two vaccines to prevent ebola in Liberia","volume":"377","author":"Kennedy","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129113_bb1430","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251101","article-title":"The impact of malaria coinfection on ebola virus disease outcomes: A systematic review and meta-analysis","volume":"16","author":"Edwards","year":"2021","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb1435","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.virol.2004.10.018","article-title":"Strong cellular and humoral anti-HIV env immune responses induced by a heterologous rhabdoviral prime-boost approach","volume":"331","author":"Tan","year":"2005","journal-title":"Virology"},{"issue":"24","key":"10.1016\/j.vaccine.2026.129113_bb1440","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa1904387","article-title":"Henao-Restrepo AM; ebola ring vaccination team in the DRC. Ebola outbreak response in the DRC with rVSV-ZEBOV-GP ring vaccination","volume":"391","author":"Muyembe","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.129113_bb1445","unstructured":"World Health Organization. Ebola virus disease - Democratic Republic of the Congo. Situation Report 1 December 2025. Geneva: WHO; 2025. Available at: https:\/\/www.who.int\/publications\/m\/item\/ebola-situation-report [Note: please verify exact URL and document date]."},{"key":"10.1016\/j.vaccine.2026.129113_bb1450","doi-asserted-by":"crossref","first-page":"S1082","DOI":"10.1093\/infdis\/jir350","article-title":"Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus","volume":"204 Suppl 3(Suppl 3)","author":"Falzarano","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129113_bb1455","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104138","article-title":"Safety and immunogenicity of intramuscular, single-dose v590 (rVSV-SARS-CoV-2 vaccine) in healthy adults: results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial","volume":"82","author":"Robbins","year":"2022","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129113_bb1460","doi-asserted-by":"crossref","first-page":"2251595","DOI":"10.1080\/22221751.2023.2251595","article-title":"Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen","volume":"12","author":"Jelinski","year":"2023","journal-title":"Emerg Microbes Infect."},{"issue":"419","key":"10.1016\/j.vaccine.2026.129113_bb1465","doi-asserted-by":"crossref","first-page":"8848","DOI":"10.1126\/scitranslmed.aan8848","article-title":"A randomized controlled safety\/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection","volume":"9","author":"Sneller","year":"2017","journal-title":"Sci Transl Med"},{"issue":"16","key":"10.1016\/j.vaccine.2026.129113_bb1470","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1016\/j.vaccine.2023.03.015","article-title":"HIV vaccine trials network 112 protocol team. Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype c env in a randomized controlled clinical trial","volume":"41","author":"Wilson","year":"2023","journal-title":"Vaccine"},{"issue":"48","key":"10.1016\/j.vaccine.2026.129113_bb1475","doi-asserted-by":"crossref","first-page":"7171","DOI":"10.1016\/j.vaccine.2018.09.009","article-title":"Safety of the rVSV ZEBOV vaccine against ebola Zaire among frontline workers in guinea","volume":"37","author":"Juan-Giner","year":"2019","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129113_bb1480","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1093\/infdis\/jix189","article-title":"Helmond FA; v920-012 study team. Six-month safety data of recombinant vesicular stomatitis virus-Zaire ebola virus envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults","volume":"215","author":"Halperin","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129113_bb1485","doi-asserted-by":"crossref","unstructured":"Gsell PS, Camacho A, Kucharski AJ, Watson CH, Bagayoko A, Nadlaou SD, Dean NE, Diallo A, Diallo A, Honora DA, Doumbia M, Enwere G, Higgs ES, Mauget T, Mory D, Riveros X, Oumar FT, Fallah M, Toure A, Vicari AS, Longini IM, Edmunds WJ, Henao-Restrepo AM, Kieny MP, K\u00e9\u00efta S. Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of ebola virus disease in guinea, 2016: an operational and vaccine safety report. Lancet Infect Dis. 2017;17(12):1276-1284. Erratum in: Lancet Infect Dis 2017;17 (12):1232.","DOI":"10.1016\/S1473-3099(17)30541-8"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129113_bb1490","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/infdis\/jiy698","article-title":"PREVAIL i cluster vaccination study with rVSV\u0394G-ZEBOV-GP as part of a public health response in Liberia","volume":"219","author":"Bolay","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129113_bb1495","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2025.108171","article-title":"Immunogenicity and safety of ebola vaccines in children: A systematic review and meta-analysis","volume":"162","author":"Zarro","year":"2026","journal-title":"Int J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129113_bb1500","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2021-005726","article-title":"Algorithm for the support of non-related (serious) adverse events in an ebola vaccine trial in the Democratic Republic of the Congo","volume":"6","author":"Lemey","year":"2021","journal-title":"BMJ Glob Health"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129113_bb1505","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/infdis\/jiz241","article-title":"V920-012 study team. Immunogenicity, lot consistency, and extended safety of rVSV\u0394G-ZEBOV-GP vaccine: A phase 3 randomized, double-blind, placebo-controlled study in healthy adults","volume":"220","author":"Halperin","year":"2019","journal-title":"J Infect Dis"},{"issue":"26","key":"10.1016\/j.vaccine.2026.129113_bb1510","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2200072","article-title":"Randomized trial of vaccines for Zaire ebola virus disease","volume":"387","author":"Kieh","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129113_bb1515","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/trstmh\/trab180","article-title":"Ebola virus disease in pregnancy: A systematic review and meta-analysis","volume":"116","author":"Kayem","year":"2022","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb1520","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12879-025-12442-9","article-title":"Access to licenced vaccines for high-threat infectious diseases: A scoping review and interpretive analysis of ebola virus disease","volume":"26","author":"Diepvens","year":"2026","journal-title":"BMC Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129113_bb1525","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.1056","article-title":"High frequency of type i interferon auto-antibodies in a group of middle-aged HIV-infected patients: A cross-sectional exploratory study","volume":"11","author":"Imberti","year":"2023","journal-title":"Immun Inflamm Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb1530","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1055\/s-0041-1724106","article-title":"Lack of molecular mimicry between nonhuman primates and infectious pathogens: the possible genetic bases","volume":"8","author":"Kanduc","year":"2021","journal-title":"Glob Med Genet"},{"issue":"13","key":"10.1016\/j.vaccine.2026.129113_bb1535","doi-asserted-by":"crossref","first-page":"6773","DOI":"10.1128\/JVI.00649-15","article-title":"Particle-to-PFU ratio of ebola virus influences disease course and survival in cynomolgus macaques","volume":"89","author":"Alfson","year":"2015","journal-title":"J Virol"},{"issue":"17","key":"10.1016\/j.vaccine.2026.129113_bb1540","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1056\/NEJM200004273421701","article-title":"Clinical features of nipah virus encephalitis among pig farmers in Malaysia","volume":"342","author":"Goh","year":"2000","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2026.129113_bb1545","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3201\/eid2309.161922","article-title":"Convergence of humans, bats, trees, and culture in nipah virus transmission","volume":"23","author":"Gurley","year":"2017","journal-title":"Bangladesh. Emerg Infect Dis."},{"issue":"7","key":"10.1016\/j.vaccine.2026.129113_bb1550","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1086\/529147","article-title":"Clinical presentation of nipah virus infection in Bangladesh","volume":"46","author":"Hossain","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129113_bb1555","doi-asserted-by":"crossref","first-page":"107990","DOI":"10.1016\/j.ijantimicag.2026.107990","article-title":"Duan Guangcai Nipah virus: an exceptionally virulent emerging zoonotic pathogen","volume":"31","author":"Sun","year":"2026","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.vaccine.2026.129113_bb1560","doi-asserted-by":"crossref","first-page":"1517244","DOI":"10.3389\/fimmu.2025.1517244","article-title":"Cross-protectivity of henipavirus soluble glycoprotein in an in vivo model of nipah virus disease","volume":"16","author":"Findlay-Wilson","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.129113_bb1565","doi-asserted-by":"crossref","unstructured":"Kuppalli K, Lokudu R, Azman AS, et al. Reconsidering the rVSVDG-ZEBOV-GP vaccine during the 2026 Bundibugyo virus outbreak. Lancet Infect Dis 2026. doi:https:\/\/doi.org\/10.1016\/S1473-3099(26)00382-8.","DOI":"10.1016\/S1473-3099(26)00382-8"},{"key":"10.1016\/j.vaccine.2026.129113_bb1570","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJMra2607216","article-title":"Bundibugyo virus disease in 2026: clinical and public health responses","volume":"395","author":"Sullivan","year":"2026","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb1575","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ana.21178","article-title":"Long-term neurological and functional outcome in nipah virus infection","volume":"62","author":"Sejvar","year":"2007","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb1580","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/1531-8249(199909)46:3<428::AID-ANA23>3.0.CO;2-I","article-title":"The neurological manifestations of nipah virus encephalitis, a novel paramyxovirus","volume":"46","author":"Lee","year":"1999","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129113_bb1585","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3201\/eid1202.051247","article-title":"Nipah virus-associated encephalitis outbreak, Siliguri","volume":"12","author":"Chadha","year":"2006","journal-title":"India. Emerg Infect Dis."},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb1590","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3390\/microorganisms13010124","article-title":"Nipah virus: A zoonotic threat re-emerging in the wake of global public health challenges","volume":"13","author":"Branda","year":"2025","journal-title":"Microorganisms"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129113_bb1595","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s12275-024-00168-3","article-title":"Recent advances of nipah virus disease: pathobiology to treatment and vaccine advancement","volume":"62","author":"Saha","year":"2024","journal-title":"J Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb1600","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1017\/S0317167100001785","article-title":"Nipah encephalitis outbreak in Malaysia, clinical features in patients from seremban","volume":"29","author":"Chong","year":"2002","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.vaccine.2026.129113_bb1605","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0002-9440(10)64493-8","article-title":"Nipah virus infection: pathology and pathogenesis of an emerging paramyxoviral zoonosis","volume":"161","author":"Wong","year":"2002","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb1620","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/jnnp.74.1.131","article-title":"Late clinical and magnetic resonance imaging follow up of nipah virus infection","volume":"74","author":"Lim","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb1610","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/cid\/ciz789","article-title":"Clinical manifestations of nipah virus-infected patients who presented to the emergency department during an outbreak in Kerala state in India, may 2018","volume":"71","author":"Chandni","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129113_bb1615","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/IIO.0000000000000539","article-title":"Emerging infectious diseases and the eye: ophthalmic manifestations, pathogenesis, and one health perspectives","volume":"64","author":"Blyden","year":"2024","journal-title":"Int Ophthalmol Clin"},{"issue":"21","key":"10.1016\/j.vaccine.2026.129113_bb1625","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01136-17","article-title":"Nipah and hendra virus nucleoproteins inhibit nuclear accumulation of signal transducer and activator of transcription 1 (STAT1) and STAT2 by interfering with their complex formation","volume":"91","author":"Sugai","year":"2017","journal-title":"J Virol"},{"issue":"8","key":"10.1016\/j.vaccine.2026.129113_bb1630","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.3390\/cells9081913","article-title":"The intrinsically disordered w protein is multifunctional during henipavirus infection, disrupting host signalling pathways and nuclear import","volume":"9","author":"Tsimbalyuk","year":"2020","journal-title":"Cells"},{"issue":"19","key":"10.1016\/j.vaccine.2026.129113_bb1635","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1056\/NEJMoa1805376","article-title":"Transmission of nipah virus - 14 years of investigations in Bangladesh","volume":"380","author":"Nikolay","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129113_bb1640","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.70445","article-title":"Detection of nipah virus in human milk: A novel finding","volume":"97","author":"Rahman","year":"2025","journal-title":"J Med Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129113_bb1645","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1086\/520822","article-title":"In utero transmission of nipah virus: role played by pregnancy and vertical transmission in henipavirus epidemiology","volume":"196","author":"Dimitrov","year":"2007","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129113_bb1650","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1086\/520818","article-title":"Vertical transmission and fetal replication of nipah virus in an experimentally infected cat","volume":"196","author":"Mungall","year":"2007","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb1655","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3201\/eid1901.120221","article-title":"Risk factors for nipah virus infection among pteropid bats, peninsular Malaysia","volume":"19","author":"Rahman SA, Hassan L, Epstein JH, Mamat ZC, Yatim AM, Hassan SS, Field HE, Hughes T, Westrum J, Naim MS, Suri AS, Jamaluddin AA, Daszak P; Henipavirus Ecology Research Group","year":"2013","journal-title":"Emerg Infect Dis"},{"issue":"1636","key":"10.1016\/j.vaccine.2026.129113_bb1660","first-page":"861","article-title":"Reproduction and nutritional stress are risk factors for hendra virus infection in little red flying foxes (pteropus scapulatus)","volume":"275","author":"Plowright","year":"2008","journal-title":"Proc Biol Sci"},{"issue":"2045","key":"10.1016\/j.vaccine.2026.129113_bb1665","first-page":"20242381","article-title":"A global-scale dataset of bat viral detection suggests that pregnancy reduces viral shedding","volume":"292","author":"Eskew","year":"2025","journal-title":"Proc Biol Sci."},{"key":"10.1016\/j.vaccine.2026.129113_bb1670","article-title":"Interpreting the natural history and pathogenesis of nipah virus disease through clinical data, to inform clinical trial design: A systematic review. Lancet","author":"Hassan","year":"2026","journal-title":"Microbe"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb1675","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1017\/S0950268801006422","article-title":"A survey of nipah virus infection among various risk groups in Singapore","volume":"128","author":"Chan","year":"2002","journal-title":"Epidemiol Infect"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129113_bb1680","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1086\/647951","article-title":"Transmission of human infection with nipah virus","volume":"49","author":"Luby","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129113_bb1685","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.3201\/eid1812.120875","article-title":"Transmission routes for nipah virus from Malaysia and Bangladesh","volume":"18","author":"Clayton","year":"2012","journal-title":"Emerg Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129113_bb1690","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.3201\/eid1012.040701","article-title":"Nipah virus encephalitis reemergence","volume":"10","author":"Hsu","year":"2004","journal-title":"Bangladesh. Emerg Infect Dis."},{"issue":"46","key":"10.1016\/j.vaccine.2026.129113_bb1695","doi-asserted-by":"crossref","first-page":"29190","DOI":"10.1073\/pnas.2000429117","article-title":"Nipah virus dynamics in bats and implications for spillover to humans","volume":"117","author":"Epstein","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129113_bb1700","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3201\/eid1902.120971","article-title":"Nipah virus infection outbreak with nosocomial and corpse-to-human transmission","volume":"19","author":"Sazzad","year":"2013","journal-title":"Bangladesh Emerg Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129113_bb1705","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1093\/cid\/ciz010","article-title":"Adaptive immune responses in humans during nipah virus acute and convalescent phases of infection","volume":"69","author":"Arunkumar","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb1710","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/jinf.2000.0782","article-title":"The presence of nipah virus in respiratory secretions and urine of patients during an outbreak of nipah virus encephalitis in Malaysia","volume":"42","author":"Chua","year":"2001","journal-title":"J Infect"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129113_bb1715","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.4103\/jfmpc.jfmpc_1731_21","article-title":"Sero-prevalence of nipah antibodies among close contacts of the index case during 2019 ernakulam outbreak","volume":"11","author":"Ramachandran","year":"2022","journal-title":"J Family Med Prim Care"},{"key":"10.1016\/j.vaccine.2026.129113_bb1720","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/tropicalmed8010016","article-title":"Vertical transfer of humoral immunity against nipah virus: A novel evidence from Bangladesh","volume":"8","author":"Satter","year":"2022","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129113_bb1725","first-page":"123","article-title":"Nipah and hendra virus interactions with the innate immune system","volume":"359","author":"Basler","year":"2012","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2026.129113_bb1730","doi-asserted-by":"crossref","unstructured":"Pelissier R, Iampietro M, Horvat B. Recent advances in the understanding of Nipah virus immunopathogenesis and anti-viral approaches. F1000Res. 2019;8:F1000 Faculty Rev-1763. doi:10.12688\/f1000research.19975.1.","DOI":"10.12688\/f1000research.19975.1"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb1735","doi-asserted-by":"crossref","first-page":"16710","DOI":"10.1038\/s41598-019-53037-0","article-title":"Antagonism of STAT1 by nipah virus p gene products modulates disease course but not lethal outcome in the ferret model","volume":"9","author":"Satterfield","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.129113_bb1740","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2010.05.005","article-title":"Characterization of the antiviral and inflammatory responses against nipah virus in endothelial cells and neurons","volume":"404","author":"Lo","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2026.129113_bb1745","doi-asserted-by":"crossref","DOI":"10.1016\/j.coviro.2026.101509","article-title":"Immune evasion and pathogenesis of henipaviruses","volume":"74","author":"Kim","year":"2026","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2026.129113_bb1750","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2025.108263","article-title":"Insights into the acute phase of nipah virus infection: clinical features, viral detection, and humoral immune response","volume":"163","author":"Satter","year":"2026","journal-title":"Int J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129113_bb1755","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/ana.10212","article-title":"Relapsed and late-onset nipah encephalitis","volume":"51","author":"Tan","year":"2002","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb1760","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41541-024-01036-2","article-title":"Establishing an immune correlate of protection for nipah virus in nonhuman primates","volume":"9","author":"Leyva-Grado","year":"2024","journal-title":"NPJ Vaccines."},{"issue":"Pt 9","key":"10.1016\/j.vaccine.2026.129113_bb1765","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1099\/0022-1317-82-9-2151","article-title":"Complete nucleotide sequences of nipah virus isolates from Malaysia","volume":"82","author":"Chan","year":"2001","journal-title":"J Gen Virol"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129113_bb1770","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000642","article-title":"A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection","volume":"5","author":"Bossart","year":"2009","journal-title":"PLoS Pathog"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb1775","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/jmv.24345","article-title":"Origin and evolution of nipah virus","volume":"88","author":"Lo Presti","year":"2016","journal-title":"J Med Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129113_bb1780","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1006\/viro.2002.1677","article-title":"Recombinant chimeric western and eastern equine encephalitis viruses as potential vaccine candidates","volume":"302","author":"Schoepp","year":"2002","journal-title":"Virology"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129113_bb1785","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1073\/pnas.88.12.5139","article-title":"Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus","volume":"88","author":"Lai","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb1790","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1128\/JVI.02308-14","article-title":"Rhabdovirus-based vaccine platforms against henipaviruses","volume":"89","author":"Kurup","year":"2015","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129113_bb1795","article-title":"Replication, safety and immunogenicity of the vectored ebola vaccine rVSV-\u0394G-ZEBOV-GP in a sub-Saharan african paediatric population: A randomised controlled, open-label trial in children aged 1-12 years living in Lambar\u00e9n\u00e9, Gabon","volume":"89","author":"Alabi A, Kokou K, Mahmoudou S, Kavishna R, Nakka SS, Rothenberger S, Musangomunei FP, Olubiyi BF, Bie-Ondo JC, Kabwende AL, Velavan TP; VSV-EBOPLUS Consortium; Medaglini D, Nakaya HI, Engler O, Harandi AM, Siegrist CA, Kremsner PG, Agnandji ST","year":"2024","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb1800","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/viro.1997.8681","article-title":"New insights into the mechanisms of RNA recombination","volume":"235","author":"Nagy","year":"1997","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb1805","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3201\/eid3103.241134","article-title":"Genetic diversity and geographic spread of henipaviruses","volume":"31","author":"Kane","year":"2025","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129113_bb1810","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/v15051077","article-title":"A recombinant chimeric cedar virus-based surrogate neutralization assay platform for pathogenic henipaviruses","volume":"15","author":"Amaya","year":"2023","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129113_bb1815","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1073\/pnas.88.4.1379","article-title":"Cells that express all five proteins of vesicular stomatitis virus from cloned cDNAs support replication, assembly, and budding of defective interfering particles","volume":"88","author":"Pattnaik","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt. 1","key":"10.1016\/j.vaccine.2026.129113_bb1820","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1099\/0022-1317-60-1-87","article-title":"Analysis of viral and defective-interfering nucleocapsids in acute and persistent infection by rhabdoviruses","volume":"60","author":"Grabau","year":"1982","journal-title":"J Gen Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129113_bb1825","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/JVI.78.2.958-967.2004","article-title":"Persistent infection with ebola virus under conditions of partial immunity","volume":"78","author":"Gupta","year":"2004","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb1830","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s13311-016-0457-z","article-title":"Neurological complications of ebola virus infection","volume":"13","author":"Billioux","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129113_bb1835","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jcpa.2007.03.002","article-title":"Experimental nipah virus infection in pteropid bats (pteropus poliocephalus)","volume":"136","author":"Middleton","year":"2007","journal-title":"J Comp Pathol"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129113_bb1840","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005120","article-title":"Identifying early target cells of nipah virus infection in Syrian hamsters","volume":"10","author":"Baseler","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2026.129113_bb1845","first-page":"6","article-title":"Kinetics of IgM and IgG seroconversion in nipah virus infection","volume":"5","author":"Ramasundram","year":"2000","journal-title":"Neurol J Southeast Asia"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129113_bb1850","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1128\/JVI.80.4.1972-1978.2006","article-title":"Antibody prophylaxis and therapy against nipah virus infection in hamsters","volume":"80","author":"Guillaume","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.129113_bb1855","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/9781394188741.ch12","article-title":"Recent advances in combating nipah virus disease","author":"Chorawala","year":"2024","journal-title":"In Rising Contagious Diseases"},{"issue":"40","key":"10.1016\/j.vaccine.2026.129113_bb1860","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1016\/j.vaccine.2016.08.028","article-title":"Protection against henipaviruses in swine requires both, cell-mediated and humoral immune response","volume":"34","author":"Pickering","year":"2016","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129113_bb1865","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112402","article-title":"Antibodies against the ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates","volume":"42","author":"Gunn","year":"2023","journal-title":"Cell Rep"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129113_bb1870","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1093\/infdis\/jiad557","article-title":"Characterization of humoral responses to nipah virus infection in the Syrian hamster model of disease","volume":"230","author":"Scholte","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129113_bb1875","article-title":"Immunological correlate of protection by PHV02 live, attenuated recombinant VSV vaccine against nipah virus disease using an improved neutralizing antibody method, with considerations for future research","author":"Monath","year":"2026","journal-title":"NPJ Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129113_bb1880","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3390\/vaccines13060608","article-title":"Vaccines and animal models of nipah virus: current situation and future prospects","volume":"13","author":"Lv","year":"2025","journal-title":"Vaccines (Basel)."},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb1885","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.tvjl.2008.12.009","article-title":"Animal models for the study of emerging zoonotic viruses: Nipah and hendra","volume":"181","author":"Horvat","year":"2009","journal-title":"Vet J"},{"key":"10.1016\/j.vaccine.2026.129113_bb1890","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/ncomms1796","article-title":"Bats host major mammalian paramyxoviruses","volume":"3","author":"Drexler","year":"2012","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb1895","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1186\/s12916-024-03726-z","article-title":"RVSV-ZEBOV vaccination in people with pre-existing immunity to ebolavirus: an open-label safety and immunogenicity study in guinean communities affected by ebola virus disease (l\u2019essai proches)","volume":"22","author":"Watson","year":"2024","journal-title":"BMC Med"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129113_bb1900","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1080\/15459620701329012","article-title":"Inactivation of viruses on surfaces by ultraviolet germicidal irradiation","volume":"4","author":"Tseng","year":"2007","journal-title":"J Occup Environ Hyg"},{"key":"10.1016\/j.vaccine.2026.129113_bb1905","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fvets.2019.00016","article-title":"Vaccine development for nipah virus infection in pigs","volume":"6","author":"McLean","year":"2019","journal-title":"Front Vet Sci"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129113_bb1910","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0749-0720(02)00038-5","article-title":"Menangle and nipah virus infections of pigs","volume":"18","author":"Kirkland","year":"2002","journal-title":"Vet Clin North Am Food Anim Pract"},{"issue":"24","key":"10.1016\/j.vaccine.2026.129113_bb1915","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"PALM Consortium Study Team. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.129113_bb1920","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.721328","article-title":"Insights on current FDA-approved monoclonal antibodies against ebola virus infection","volume":"12","author":"Tshiani Mbaya","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.129113_bb1925","article-title":"A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge","volume":"3(105):105ra103","author":"Bossart","year":"2011","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129113_bb1930","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1473-3099(19)30634-6","article-title":"Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the g glycoprotein of henipaviruses in healthy adults: A first-in-human, randomised, controlled, phase 1 study","volume":"20","author":"Playford","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129113_bb1935","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/s41594-019-0308-9","article-title":"An antibody against the f glycoprotein inhibits nipah and hendra virus infections","volume":"26","author":"Dang","year":"2019","journal-title":"Nat Struct Mol Biol"},{"issue":"21","key":"10.1016\/j.vaccine.2026.129113_bb1940","doi-asserted-by":"crossref","first-page":"11457","DOI":"10.1128\/JVI.01318-12","article-title":"Biochemical, conformational, and immunogenic analysis of soluble trimeric forms of henipavirus fusion glycoproteins","volume":"86","author":"Chan","year":"2012","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129113_bb1945","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2024.101002","article-title":"Therapeutics for nipah virus disease: A systematic review to support prioritisation of drug candidates for clinical trials","volume":"6","author":"Chan","year":"2025","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2026.129113_bb1950","doi-asserted-by":"crossref","unstructured":"G\u00f3mez Rom\u00e1n R, Tornieporth N, Cherian NG, Set al.. Medical countermeasures against henipaviruses: A review and public health perspective. Lancet Infect Dis 2022;22(1):e13-e27.","DOI":"10.1016\/S1473-3099(21)00400-X"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129113_bb1955","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1038\/jcbfm.2013.160","article-title":"Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier","volume":"33","author":"St-Amour","year":"2013","journal-title":"J Cereb Blood Flow Metab"},{"issue":"13","key":"10.1016\/j.vaccine.2026.129113_bb1960","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1128\/JVI.00135-10","article-title":"Viral entry inhibitors targeted to the membrane site of action","volume":"84","author":"Porotto","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.129113_bb1965","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104592","article-title":"Cholesterol-conjugated stapled peptides inhibit ebola and Marburg viruses in vitro and in vivo","volume":"171","author":"Pessi","year":"2019","journal-title":"Antiviral Res"},{"issue":"9","key":"10.1016\/j.vaccine.2026.129113_bb2130","first-page":"741","article-title":"Interferon induction as a quasispecies marker of vesicular stomatitis virus populations","volume":"18","author":"Marcus","year":"1998","journal-title":"J Interferon Cytokine Res"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129113_bb1970","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/77558","article-title":"Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus","volume":"6","author":"Stojdl","year":"2000","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb1975","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/v17010016","article-title":"Employing the oncolytic vesicular stomatitis virus in cancer virotherapy: resistance and clinical considerations","volume":"17","author":"Abdelmageed","year":"2024","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129113_bb1980","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3390\/ph12040142","article-title":"Tamoxifen protects from vesicular stomatitis virus infection","volume":"12","author":"Cham","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129113_bb1985","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1128\/AAC.29.6.1010","article-title":"Effect of ribavirin on macromolecular synthesis in vesicular stomatitis virus-infected cells","volume":"29","author":"Toltzis","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2026.129113_bb1990","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2014.10.035","article-title":"Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector","volume":"475","author":"Wollmann","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2026.129113_bb1995","unstructured":"World Health Organization. Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines. WHO Technical Report Series, No. 978, Annex 5. Geneva: WHO; 2012. Available from: https:\/\/www.who.int\/biologicals\/areas\/vaccines\/TRS_978_Annex_5.pdf."},{"issue":"6","key":"10.1016\/j.vaccine.2026.129113_bb2000","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02154-16","article-title":"Chikungunya, influenza, nipah, and semliki forest chimeric viruses with vesicular stomatitis virus: actions in the brain","volume":"91","author":"van den Pol","year":"2017","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb2005","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/infdis\/jis653","article-title":"Type i interferon signaling protects mice from lethal henipavirus infection","volume":"207","author":"Dhondt","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129113_bb2010","article-title":"Human life within a narrow range: the lethal ups and downs of type i interferons","volume":"9(97):eadm8185","author":"Crow","year":"2024","journal-title":"Sci Immunol"},{"key":"10.1016\/j.vaccine.2026.129113_bb2015","unstructured":"Food and Drug Administration. ERVEBO (Ebola Zaire vaccine, live). Package insert [updated 2023]. Silver Spring, MD: FDA; 2023. Available from: https:\/\/www.fda.gov\/files\/vaccines%2C%20blood%20%26%20biologics\/published\/Package-Insert-ERVEBO_1.pdf."},{"issue":"Suppl. 7","key":"10.1016\/j.vaccine.2026.129113_bb2020","doi-asserted-by":"crossref","first-page":"S660","DOI":"10.1093\/infdis\/jiad157","article-title":"A highly attenuated panfilovirus VesiculoVax vaccine rapidly protects nonhuman primates against Marburg virus and 3 species of ebola virus","volume":"228","author":"Woolsey","year":"2023","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129113_bb2025","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/ni1519","article-title":"Immunopathology of highly virulent pathogens: insights from ebola virus","volume":"8","author":"Zampieri","year":"2007","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129113_bb2030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060838","article-title":"Lectin-dependent enhancement of ebola virus infection via soluble and transmembrane c-type lectin receptors","volume":"8","author":"Brudner","year":"2013","journal-title":"PloS One"},{"issue":"9","key":"10.1016\/j.vaccine.2026.129113_bb2035","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1080\/21645515.2016.1183857","article-title":"Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection","volume":"12","author":"Lauretti","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129113_bb2040","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02345-20","article-title":"Mucosal delivery of recombinant vesicular stomatitis virus vectors expressing envelope proteins of respiratory syncytial virus induces protective immunity in cotton rats","volume":"95","author":"Binjawadagi","year":"2021","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb2045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002024","article-title":"Comparison of the pathogenicity of nipah virus isolates from Bangladesh and Malaysia in the Syrian hamster","volume":"7","author":"DeBuysscher","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2026.129113_bb2050","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3390\/pathogens12080976","article-title":"Establishment of a nipah virus disease model in hamsters, including a comparison of intranasal and intraperitoneal routes of challenge","volume":"12","author":"Findlay-Wilson","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2026.129113_bb2055","doi-asserted-by":"crossref","first-page":"1518358","DOI":"10.3389\/fvets.2025.1518358","article-title":"Pathology and host-pathogen interactions in a golden Syrian hamster model of nipah virus infection","volume":"12","author":"Ruedas-Torres","year":"2025","journal-title":"Front Vet Sci"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129113_bb2060","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/infdis\/jiy357","article-title":"Experimental infection of Syrian hamsters with aerosolized nipah virus","volume":"218","author":"Escaffre","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129113_bb2065","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/srep00736","article-title":"Rapid nipah virus entry into the central nervous system of hamsters via the olfactory route","volume":"2","author":"Munster","year":"2012","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129113_bb2070","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01597-19","article-title":"Progress in elucidating potential markers and mechanisms of rapid protection conferred by the VSV-vectored ebola virus vaccine","volume":"10","author":"Wong","year":"2019","journal-title":"mBio"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129113_bb2075","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2025.101244","article-title":"Fast-acting single-dose vesicular stomatitis virus-Sudan virus vaccine: A challenge study in macaques","volume":"6","author":"Fletcher","year":"2025","journal-title":"Lancet Microbe."},{"key":"10.1016\/j.vaccine.2026.129113_bb2080","series-title":"Low-dose VSV-EBOV vaccination provides rapid protection from lethal Ebola virus challenge. bioRxiv [Preprint]. 2026:2026.02.14.705917","author":"Marzi","year":"2026"},{"key":"10.1016\/j.vaccine.2026.129113_bb2085","first-page":"1144325","article-title":"Characterization of interventional clinical trials for monkeypox; systematic review of ClinicalTrials.Gov database. Front","volume":"11","author":"Alorfi","year":"2023","journal-title":"Public Health"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb2090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2003.12.016","article-title":"The blood-brain barrier: an overview: structure, regulation, and clinical implications","volume":"16","author":"Ballabh","year":"2004","journal-title":"Neurobiol Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129113_bb2095","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13045-020-00986-z","article-title":"Immunosenescence: A key player in cancer development","volume":"13","author":"Lian","year":"2020","journal-title":"J Hematol Oncol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26009229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26009229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:55:25Z","timestamp":1793922925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26009229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":426,"alternative-id":["S0264410X26009229"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129113","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"rVSV-\u0394G-EBOV-GP-Nipah-G (also designated PHV02) replication-competent, recombinant vesicular stomatitis virus vaccine for prevention of Nipah virus disease: Standardized template with key considerations for a risk\/benefit assessment","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"129113"}}